Characterization of chemical constituents from Sicyos angulatus and Ambrosia artemisiifolia using molecular networking and mass defect filtering by 안진표
 
 
저 시-비 리- 경 지 2.0 한민  
는 아래  조건  르는 경 에 한하여 게 
l  저 물  복제, 포, 전송, 전시, 공연  송할 수 습니다.  
다 과 같  조건  라야 합니다: 
l 하는,  저 물  나 포  경 ,  저 물에 적 된 허락조건
 명확하게 나타내어야 합니다.  
l 저 터  허가를 면 러한 조건들  적 되지 않습니다.  
저 에 른  리는  내 에 하여 향  지 않습니다. 




저 시. 하는 원저 를 시하여야 합니다. 
비 리. 하는  저 물  리 목적  할 수 없습니다. 




Characterization of chemical constituents from 
Sicyos angulatus and Ambrosia artemisiifolia 
using molecular networking and mass defect 
filtering 
 
Molecular networking과 mass defect filtering을 
적용한 가시박과 돼지풀 유래 화학 성분 연구 
 
 
2019 년 8 월 
 
서울대학교 대학원 




Characterization of chemical constituents from Sicyos 
angulatus and Ambrosia artemisiifolia using molecular 
networking and mass defect filtering 
Molecular networking과 mass defect filtering을 적용한 
가시박과 돼지풀 유래 화학 성분 연구 
 
지도교수 오 원 근 
 
이 논문을 약학박사 학위논문으로 제출함 




안 진 표 
 
안진표의 약학박사 학위논문을 인준함 
2019 년 8 월 
 
위 원 장                         (인) 
부위원장                         (인) 
위      원                         (인) 
위      원                         (인) 





Characterization of chemical constituents from Sicyos 
angulatus and Ambrosia artemisiifolia using molecular 
networking and mass defect filtering 
 
Part 1 
A library of extracted natural materials (Korea Bioactive Natural Material Bank) 
have been screened to discover candidates for the treatment of non-alcoholic liver 
disease (NAFLD), and the 70% ethanol extract of Sicyos angulatus was found to 
inhibit hepatic lipid accumulation. Bioassay–guided fractionation of this bioactive 
extract yielded five previously undescribed flavonoid glycosides (1, 8, 9, 11, and 12) 
and one previously undescribed flavonolignan glycoside (13) along with seven 
known flavonoid glycosides (2-7, and 10). The chemical structures of these 
compounds were elucidated by a combination of extensive spectroscopic analysis, 
including MS, NMR, and UV techniques. Compounds 1-4, 6, and 11-13 showed 
inhibitory effects on the lipid accumulation induced by high concentrations of 
palmitic acid and glucose in HepG2 cells. Four selected compounds (1, 3, 4, and 13) 
were tested for lipid content in a dose-dependent manner (10, 20, and 40 μM), and 
among those compounds, kaempferol 3-O-β-D-glucopyranosyl-7-O-α-L-
rhamnopyranoside (4) showed the strongest inhibition of hepatic lipid production in 
HepG2 cells. In an oil-red O staining assay, five compounds (1, 3, 4, 11, and 13) 
were shown to reduce hepatic lipid accumulation better than what was observed in 
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the vehicle control group. The present study suggests a new class of chemical entities 
for developing bioactive agents for the treatment of diseases caused by fat 
accumulation in the liver.  
 
Part 2 
In Alzheimer’s disease (AD), amyloid-β (Aβ) accumulation in the brain results in 
neuronal cell death and is one of the major causes of dementia. Since the current 
therapeutic agents are not yet sufficiently effective or safe, there have been 
attempts to find new neuroprotective chemicals against Aβ-induced cytotoxicity. 
A 70% EtOH extract of the whole plants of Ambroisa artemisiifolia (common 
ragweed) was selected after the screening of a natural extract library. Seven new 
eudesmane-type glycosides (1-7) and seven known compounds (8-14) were 
obtained through bioactivity-guided fractionation from the aerial parts of this 
plant. Their structures were determined on the basis of their NMR spectra, 
HRESIMS analysis, and ECD calculations. Among them, compounds 1, 2, 4-6, 8-
9, 11, and 13-14 showed protective effects against Aβ-induced cytotoxicity in 
Aβ42-transfected HT22 cells. The most active compounds, 5 and 6, exhibited 
moderate protective activity dose-dependently (10, 20, and 40 µM).  
Keywords: Sicyos angulatus, molecular networking, NAFLD, Ambrosia 
artemisiifolia, mass defect filtering, neuroprotection 
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Part 1. Flavone glycosides from Sicyos angulatus and their 













1.1. Non alcoholic fatty liver disease (NAFLD) 
Non-alcoholic fatty liver disease (NAFLD) is the starting point for the 
progression of several liver diseases such as simple steatosis, non-alcoholic 
steatohepatitis (NASH), and liver cirrhosis. Accumulation of triglycerides in the 
liver is a characteristic marker of NAFLD and an important stage in the pathogenesis 
of NAFLD, and more severe NASH is indicated by inflammation, steatosis, and 
fibrosis (Trauner et al., 2010). To date, several mechanisms have been known to be 
involved in lipid accumulation in liver, but de novo hepatic lipogenesis (DNL) and 
elevated peripheral fatty acids are considered to be the most dominant contributors 
to hepatic lipid accumulation in NAFLD (Tilg and Moschen, 2008). Approximately 
20-40% of patients with NAFLD or NASH eventually develop fibrosis and cirrhosis 
(Assy et al., 2009). NAFLD is the second most common reason for liver 
transplantation in the US and the most rapidly increasing indication for requiring 
liver transplantation in patients with hepatocellular carcinoma (HCC) (Younossi et 
al., 2016).  
The pathogenesis of NAFLD is strongly associated with the metabolic 
syndrome. The liver plays a critical role in carbohydrate metabolism as it is 
responsible for blood glucose balance through glycogenesis and glycogenolysis. 
Approximately 96% of patients with cirrhosis have glucose tolerance and 30% have 
been clinically diagnosed as diabetic, which explains the importance of controlling 
fat accumulation in the liver (Garcia-Compean et al., 2009). Even an increased risk 
of HCC has been reported to be related to metabolic factors including obesity and 
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diabetes. Fatty liver disease is usually associated with insulin resistance because 
soluble mediators from immune cells and free fatty acids are involved in the insulin 
regulation system and NAFLD manifestation (Reddy and Rao, 2006). Several 
inflammatory cytokines, including TNFα and IL-6, which are produced in a series of 
steps, are crucial triggers of a series of liver diseases such as NAFLD, NASH and 
liver cirrhosis. Several drugs are available for treat NAFLD including statin, 
metformin, and fibrates. However, these drugs are associated with adverse effects or 
contraindications (Collier., 2007). A few natural products were reported for their 
anti-NAFLD effects and few side effects were expected from natural products 
sources (Zhang et al., 2013; Xu et al., 2014). Since NAFLD has rapidly increased 
with the spread of metabolic syndrome and also with population ageing, attempts 












1.2. Sicyos angulatus 
The genus Sicyos, which contains approximately 40 species, is one of the most 
diverse genus within the family Cucurbitaceae. A Sicyos angulatus L. 
(www.theplantlist.org) (synonym Elaterium trifoliatum L.) is a vine plant that grows 
along wet areas and river banks (Figure 1). This plant is considered a troublesome 
weed because of its rapid growth, which allows it to quickly cover land and push out 
other plants (Lara-Núñez et al., 2009). S. angulatus has been introduced in Korea for 
the purpose of crossbreeding with other fruit plants, but the rapid growth of this plant 
has made it harmful to Korean wetlands. However, before the flowering, the young 
leaf of this plant is listed as an edible raw material in the Korean Food Standards 
Codex (KFSC), and thus the possibility of it being used as a source of functional 
foods has been suggested (MFDS, 2018). To date, studies on S. angulatus have 
mostly focused on ecological aspects based on the environmental hazards associated 
with this plant, and little has been reported on the chemical constituents of S. 
angulatus. Several flavonoid glycosides and sterols have been identified as chemical 
constituents of this plant, but no biological activities have been reported (Na et al., 
2013; Akihisa et al., 1987) (Figure 2). 
Recently, we orally administered the 70% EtOH extract of the leaves and stems 
of S. angulatus to apolipoprotein E-deficient (apoE−/−) mice with an atherogenic diet 
for 8 weeks, and a significant reduction in atherosclerotic plaque area in the whole 
aorta and aortic sinus was observed compared with vehicle-treated mice. In addition, 
gene expression levels of proatherogenic cytokines such as interleukin-6 (IL6) and 
tumour necrosis factor α (TNFα) were significantly decreased in the aorta of apoE−/− 
































Figure 2. Structures of chemical constituents reported in S. angulatus. 
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1.3. Molecular networking 
Mass based metabolomics has been increasingly used in natural product research. 
Molecular networking was introduced in the metabolomics field recently and this 
cutting-edge technology has led to the advance in natural product (NP) research. This 
emerging computer-based approach has been settled well because of the advance in 
mass instrumentation and data processing. Significant progression of mass 
instrumentation allows accurate detection of exact mass and chemical formula of 
large or complex dataset (Grauso et al., 2019). In addition, mass instrument 
manufactures developed advanced data analysis tool such as MassHunter, MZmine, 
Markerllynx and so on. To analysis natural products, data process is crucial and 
essential step impacting upon the quality of data output. During the process, data 
becomes more accurate and reliable. It distinguishes the metabolites from analytical 
interferences. Raw mass data contains not only metabolites but also back ground 
noises such as solvent impurities, adducts and dimers. Furthermore, the data process 
program detects the overlapping chromatographic peaks to distinguish two peak of 
very similar retention time or align the retention time between different samples. 
Combining the preprocessing efficiency and simplicity of MZmine with the 
molecular network visualization via the GNPS platform (http://gnps.ucsd.edu) 
allows rapid tentative identification as well as clustering components. Structurally 
similar compounds generate similar mass fragment. So the similarities of fragment 
pattern between two compounds can be used for grouping components (Allard et al., 
2016) (Figure 3). For example, kaempferol glycoside and quercetin glycoside 
generate different product ion fragment since their aglycone is different. Kaempferol 
glycosides share product ion of m/z 269.0450 (C15H9O5), however, at the same time, 
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quercetin glycosides share product ion of 285.0399 (C15H9O6) since quercetin has 
one more oxygen at B ring compared to kaempferol. Therefore, within a kaempferol 
glycoside group, compounds possessing same aglycone connected strongly with 
high cosine score. Likewise, based on mass fragment pattern, molecular families 
cluster together with in a network (Fox Ramos et al., 2019). There are several 
algorithms to mark similarities of each compounds such as probability-based 
matching system, normalized Euclidean distance, absolute value distance, cosine 






Figure 3. The concept of molecular network (Quinn et al., 2016) 
9 
 
This algorithm is more reliable than just matching the precursor based on 
database including Scifinder or Beilstein Dictionary of Natural Products. The MS 
fragment provides more detail and clear information such as sugar [162 (hexose), 
132 (pentose)] or acyl groups [104 (benzoyl), 82 (tigloyl) and 42 (acetyl)]. 
Furthermore, as mentioned above, the major daughter ion gives strong evidence for 
the chemical structure of the aglycone. Since the molecular networking enables 
researchers to identify compounds rapidly, many researchers have applied this 
method to dereplicate known compounds from complex mixtures. Some researchers 
use “seed” spectra to precisely dereplicate in the mixture (Yang et al., 2013). Since 
the fragment pattern of isolated compound was clearly elucidated, it enables 
researchers to predict the chemical structure of its analogues in a high level of 
confidence (Figure 4). Molecular networking also used to find the bioactive 
components from the fraction. In classical bioassay-guided fractionation, although 
the researcher find bioactivity at total extract level, subsequent fractionation may 
lead to miss the bioactive compounds or isolate previously reported well-known 
compounds such as quercetin and apigenin. However, by using the molecular 
networking, bioactivity score of each peak was predicted based on its structure. By 
using this method, bioactive compounds were properly isolated without being lost. 
For example, Nothias et al developed a bioinformatic workflow to able to map 
bioactivity score in molecular network.  
Although there are shortcomings of molecular networking due to limiting 
information on natural compounds, GNPS has collected numerous spectral libraries 
sets such as NIH, MassBank and NIST. Furthermore, the number of MS/MS spectra 
data are updated continuously by other libraries and researchers. 
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And this emerging recent analysis tool can exhibit strong synergistic effect when 
combined with conventional chemical analysis method such as UV spectrum 
analysis especially for phenolic compounds like flavonoid. Since phenolic 
compound presents strong UV spectrum, the UV information enables researchers to 
precisely confirm the peaks according to their retention time together with the results 











1.4. UV spectrum 
Molecules possessing bonding or non-bonding electrons absorb energy as 
ultraviolet to excite electrons to higher anti-bonding molecular orbitals. An electron 
is excited from a full orbital into an empty anti-bonding orbital (Figure 5). The easier 
the electrons excited, the longer the wavelength was absorbed and there are four 
types of transitions; π–π*, n–π*, σ–σ*, and n–σ*. In practice, the absorption 
frequencies for C-C, C-H and isolated C=C is difficult to differentiate (Vansco et al., 
2018). However, flavonoid structure consists of conjugated chromophoric system 
and displays characteristic UV spectrum. Thus UV spectrum present strong evidence 
for flavonoid structure and this analysis tool exhibit synergistic effect when 
combined with molecular networking.   
 
Figure 5. The excitation of electron and its relationship with UV wavelength.  
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1.5. Purpose of research 
In the screening programme for identifying anti-NAFLD agents in 
medicinal plants, the 70% ethanol extract of the leaf and stem of S. angulatus 
showed a potential inhibitory effect on hepatic lipid accumulation (Scheme 
1). Thus, the purification and structural determination of biologically active 





Scheme 1. The bio-guided isolation strategy of S. angulatus. 
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2. Materials and methods 
2.1. Plant materials 
S. angulatus was collected in August, 2015 in Gangwon province in Korea, and 
the sample was authenticated by Professor W. K. Oh at Seoul National University. 
A voucher specimen (SNU2015-0008) was deposited at the Medicinal Plant Garden 
of Seoul National University, Seoul, Korea.  
 
2.2. Chemicals, reagents and chromatography 
2.2.1. Chemistry reagents 
- Normal-phase silica gel (ZEOprep 60 40-63 µm) and Reversed-phase silica gel 
(Cosmosil 75C18-PREP) were purchased from Merck (Darmstadt, Germany). 
- SephadexTM LH-20 (a bead-formed dextran medium for gel filtration) from Sigma-
Aldrich (St. Louis, MO, USA) was used for column chromatography (CC). 
- TLC Silica gel 60 F254 (20  20 cm plate) and TLC Silica gel 60 RP-18 F254S (20  
20 cm plate) from Merck (Darmstadt, Germany).  
- Solvents for extraction and isolation were purchased from Dae Jung Pure Chemical 
Engineering Co. Ltd. (Siheung, Korea).   
- Solvents (ACN, MeOH) for HPLC chromatography were bought from HoneyWell 
Burdick & Jackson® , USA. 
- NMR solvents were purchased from Cambridge Isotope Laboratories, Inc., USA. 
2.1.2 Reagents for in vitro assay 
- 2-NBDG (Invitrogen, Eugene, OR, USA) 
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- BCA protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA) 
- Chemiluminescence Western blot detection kit (Thermo sci., Rockford, IL, USA) 
- Dexamethasone, 3-isobutyl-1-methyl-xanthine, MTT (Sigma, St. Louis, MO, USA) 
- DMEM, FBS, Trypsin (Hyclone, Logan, UT, USA) 
- Dimethyl sulfoxide (DMSO) (Junsei Chemical Co. Ltd., Tokyo, Japan)  
- Insulin (Roche, Mannheim, Germany) 
- Na+/K+ ATPase α1 antibody (Cell signaling Technology, Inc., Beverly, MA, USA) 
- Penicillin (100 U/mL), and streptomycin (100 μg/mL), calf serum, horse serum 
(Gibco, NY, USA) 
- Phosphate-buffered saline (PBS) (Takara, Shiga, Japan) 
- Polyvinylidene fluoride (PVDF) membranes (PVDF 0.45 µm, Immobilon-P., USA) 
 
2.2.2. Experimental instruments 
- Clean bench: Class II Biological Safety Cabinet, ESCO®  
- CO2 incubator: Forma Series II water jacketed CO2 incubator, THERMO 
- Evaporator: EYELA KSB-202, Japan 
- ESIMS spectrometer: Agilent Technologies 6130 Quadrupole LC/MS spectrometer 
equipped with an Agilent Technologies 1260 Infinity LC system (Agilent 
Technologies, Inc., Santa Clara, CA, USA) 
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- Fluorescence microplate reader: Spectra Max Gemini XPS, Molecular Devices, 
San Jose, CA, USA 
- Fluorescence microscope: Olympus ix70 Fluorescence Microscope, Olympus 
Corporation, Tokyo, Japan 
- HPLC system: Gilson 321 pump and Gilson UV/VIS 151 detector, USA. 
- IR spectrometer: JASCO, FT/IR-4200, USA 
- Microscope: Promo vert, China 
- NMR spectrometers: 
        Bruker 500 MHz spectrometer (Bruker, Billerica, MA USA) 
        JNM-ECA 600 MHz spectrometer (JEOL Ltd., Tokyo, Japan) 











2.3. Molecular networking 
Tandem mass spectrometry molecular networks were generated using the GNPS 
platform. The data were converted into mzXML format and imported to MZmine 
2.27. The mass detection was applied with the noise level at 1000 (for MS) and 100 
(for MS/MS). The chromatogram was convoluted with ions presenting a minimum 
height of 2000, minimum time span of 0.01 min, and m/z tolerance of 5.0 ppm. The 
parameter for deconvolution was as follows; peak duration range of 0.02-0.10 min, 
minimum peak height of 1500 and baseline level of 300. Chromatograms were 
isotope with isotopic peak grouper algorithm with a m/z tolerance of 5.0 ppm. The 
cosine score of each vector ranges from 0 to 1. To lower the complexity of the 
network, the comparison is applied between pairs of spectra that have at least three 
matched ions and at least over 0.5 of cosine score. Data were open and visualized 











2.4. Extraction and isolation schemes 
The dried leaves and stems of S. angulatus (1 kg) were extracted with 70% 
EtOH at room temperature three times for one week. The extract was 
concentrated under reduced pressure to yield a dried sample (115 g). The 
concentrated extract was then suspended in H2O and successively partitioned 
with n-hexane, EtOAc, and n-BuOH. The EtOAc fraction, which exhibited 
the strongest inhibitory activity against hepatic lipid accumulation in the 
HepG2 cell. The active fraction, EA part was chromatographed over silica gel (7 × 
50 cm; 63-200 μm particle size) and eluted with gradient mixtures of n-
hexane/EtOAc/MeOH (10:1:0 → 0:0:1, each 2 L) to afford five sub-fractions (F15). 
Fraction F4 was purified by reversed-phase silica gel CC (eluted with MeOH/H2O, 
4:6, v/v) to give 8 fractions (F4.14.8). Fraction F4.2 (500 mg) was subsequently 
separated on a silica gel column (4 × 40 cm; 63-200 μm particle size) with gradient 
mixtures of EtOAc/MeOH (9:1 → 0:1, each 2 L) to afford six sub-fractions 
(F4.2.14.2.6). Fraction 4.2.2 (120 mg) was further purified by HPLC (Gilson 
system using an Optima Pak C18 column [10  250 mm, 10 µm particle size, mobile 
phase CH3CN/H2O (18:82, v/v), flow rate 2 mL/min; UV detector wavelengths at 
205 and 254 nm) to yield compounds 3 (7.0 mg; tR = 33.4 min), 4 (3.0 mg; tR = 37.0 
min), 5 (2.0 mg; tR = 43.4 min), 6 (1.2 mg; tR = 38.0 min), 8 (2.2 mg; tR = 31.5 min), 
11 (2.3 mg; tR = 32.3 min), 12 (2.2 mg; tR = 36.3 min) and 13 (1.7 mg; tR = 38.3 min). 
Fraction 4.2.3 (220 mg) was subjected to Sephadex LH-20 column chromatography 
with a MeOH/H2O system (7:3) and afforded 4 subfractions (F4.2.3.14.2.3.4). 
Further purification of fraction 4.2.3.2. by HPLC (eluted with CH3CN/H2O, 4:1, v/v) 
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gave compounds 1 (5.0 mg; tR = 55.0 min), 2 (9.0 mg; tR = 60.0 min), 9 (1.9 mg; tR = 
50.0 min) and 10 (1.7 mg; tR = 48.0 min). Subfraction F4.2.6 was further purified by 









2.5. Chemical and spectral properties of isolated compounds 
Kaempferol 3-O-(6-O-E-feruloyl)-β-D-glucopyranosyl-7-O-α-L-rhamnopyranoside 
(1)  




D  -92.2 (c 0.5, MeOH) 
HRESIMS: m/z 769.2006 [M – H]– (calcd for 769.1985) 
UV (MeOH) λmax (log ε) 265 (3.75), 328 (3.41) nm  
IR νmax 3299, 1656, 1588, 1291, 1181, 1085 cm-1  
1H NMR data (500 MHz, DMSO-d6): See table 1  
13C NMR data (125 MHz, DMSO-d6): See table 2 
 
Kaempferol 3-O-(6-O-E-coumaroyl)-β-D-glucopyranosyl-7-O-α-L- 





D  -67.8 (c 0.2, MeOH) 
HRESIMS m/z 739.1880 [M − H]− (calcd for 739.1874) 
UV (MeOH) λmax (log ε) 266 (3.62), 319 (3.20) nm  
IR (KBr) vmax 3398, 2972, 2361, 1701 cm–1 
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 1H NMR (500 MHz, DMSO-d6): δH 8.02 (2H, d, J = 8.0 Hz, H-2', 6'), 7.38 (2H, d, J 
= 8.0 Hz, H-2''', 6'''), 7.32 (1H, d, J = 15.5 Hz, H-7'''), 6.85 (2H, d, J = 8.0 Hz, H-3', 
5'), 6.77 (2H, d, J = 8.0 Hz, H-3''', 5'''), 6.32 (1H, br s, H-6), 6.12 (1H, d, J = 15.5 Hz, 
H-8'''), 5.48 (1H, br s, H-1''''), 5.45 (1H, d, J = 7.5 Hz, H-1''), 4.24 (1H, d, J = 11.6 
Hz, H-6''a), 4.10 (1H, dd, J = 11.6, 6.0 Hz, H-6''b), 3.84 (1H, br s, H-2''''), 3.62 (1H, 
dd, J = 9.0, 2.6 Hz, H-3''''), 3.40 (1H, m, H-4''''), 3.32 (1H, m, H-5''), 3.29 (1H, m, H-
3''), 3.25 (1H, m, H-2''), 3.22 (1H, m, H-5''''), 3.19 (1H, m, H-4''), 1.10 (3H, d, J = 
6.0 Hz, H-6''''). 
13C NMR (125 MHz, DMSO-d6): δC 155.9 (C-2), 133.3 (C-3), 177.6 (C-4), 160.7 
(C-5), 99.3 (C-6), 161.5 (C-7), 94.6 (C-8), 156.9 (C-9), 105.5 (C-10), 120.6 (C-1'), 
130.2 (C-2'), 115.1 (C-3'), 160.2 (C-4'), 115.1 (C-5'), 130.2 (C-6'), 100.9 (C-1''), 74.3 
(C-2''), 76.2 (C-3''), 70.0 (C-4''), 74.1 (C-5''), 62.8 (C-6''), 124.9 (C-1'''), 130.9 (C-
2'''), 115.7 (C-3'''), 159.9 (C-4'''), 115.7 (C-5'''), 130.9 (C-6'''), 144.6 (C-7'''), 113.6 
(C-8'''), 166.2 (C-9'''), 98.3 (C-1''''), 69.8 (C-2''''), 70.2 (C-3''''), 71.6 (C-4''''), 69.7 (C-
5''''), 17.9 (C-6'''').   
 
Kaempferol-3-O-(6-O-α-L-rhamnopyranosyl)-β-D-glucopyranosyl-7-O-α-L-
rhamnoside. (3)  




D  -80.5 (c 0.2, MeOH)  
HRESIMS m/z 739.2079 [M − H]− (calcd for 739.2085). 
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UV (MeOH) λmax (log ε) 266 (3.80), 345 (3.10) nm 
IR (KBr) vmax 3400, 2970, 2938, 1698, 1617 cm–1;  
1H NMR (500 MHz, DMSO-d6): δH 8.01 (2H, d, J = 8.7 Hz, H-2', 6'), 6.88 (2H, d, J 
= 8.7 Hz, H-3', 5'), 6.77 (1H, br s, H-8), 6.44 (1H, br s, H-6), 5.54 (1H, s, H-1''''), 
5.35 (1H, d, J = 7.4 Hz, H-1''), 4.38 (1H, br s, H-1'''), 3.84 (1H, br s, H-2''''), 3.67 
(1H, d, J = 10.6 Hz, H-6''a), 3.64 (1H, dd, J = 9.6, 2.4 Hz, H-3''''), 3.48 (1H, m, H-
4''), 3.47 (1H, m, H-3'''),  3.46 (1H, m, H-2''), 3.45 (1H, m, H-5''''), 3.44 (1H, m, H-
5'''), 3.40 (1H, m, H-2'''), 3.34 (1H, m, H-3''), 3.22 (1H, m, H-6''b), 3.20 (1H, m, H-
4''), 3.19 (1H, m, H-4''''), 3.11 (1H, m, H-4'''), 3.10 (1H, m, H-5''), 1.11 (3H, d, J = 
6.0 Hz, H-6''''), 0.97 (3H, d, J = 6.0 Hz, H-6'''). 
13C NMR (125 MHz, DMSO-d6): δC 156.0 (C-2), 133.5 (C-3), 177.6 (C-4), 160.8 
(C-5), 99.3 (C-6), 161.6 (C-7), 94.6 (C-8), 157.2 (C-9), 105.6 (C-10), 120.6 (C-1'), 
130.9 (C-2'), 115.1 (C-3'), 160.2 (C-4'), 115.1 (C-5'), 130.9 (C-6'), 101.2 (C-1''), 74.1 
(C-2''), 76.3 (C-3''), 70.3 (C-4''), 75.8 (C-5''), 66.7 (C-6''), 100.7 (C-1'''), 70.2 (C-2'''), 
70.5 (C-3'''), 71.8 (C-4'''), 68.2 (C-5'''), 17.7 (C-6'''), 98.3 (C-1''''), 69.8 (C-2''''), 70.0 
(C-3''''), 71.6 (C-4''''), 69.8 (C-5''''), 17.9 (C-6''''). 
 
Kaempferol-3-O-β-D-glucopyranosyl-7-O-α-L-rhamnoside. (4)  




D  50.6 (c 0.2, MeOH)  
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HRESIMS m/z 593.1502 [M - H]− (calcd for 593.1506).  
UV (MeOH) λmax (log ε) 266 (3.30), 343 (3.05) nm 
IR (KBr) vmax 3709, 2971, 2870, 1698 cm–1 
1H NMR (400 MHz, DMSO-d6): δH 8.07 (2H, d, J = 8.8 Hz, H-2', 6'), 6.88 (2H, d, J 
= 8.8 Hz, H-3', 5'), 6.82 (1H, br s, H-8), 6.44 (1H, br s, H-6), 5.54 (1H, s, H-1'''), 5.47 
(1H, d, J = 7.3 Hz, H-1''), 3.83 (1H, br s, H-2'''), 3.64 (1H, dd, J = 9.3, 2.4 Hz, H-3'''), 
3.53 (1H, d, J = 11.6 Hz, H-6''a), 3.48 (1H, m, H-5''), 3.45 (1H, m, H-5'''), 3.34 (1H, 
m, H-3''), 3.32 (1H, m, H-6''b), 3.27 (1H, m, H-2''), 3.46 (1H, m, H-3''), 3.19 (1H, m, 
H-4'''), 1.11 (3H, d, J = 6.0 Hz, H-6'''). 
13C NMR (100 MHz, DMSO-d6): δC 156.0 (C-2), 133.4 (C-3), 177.5 (C-4), 160.9 
(C-5), 99.4 (C-6), 161.5 (C-7), 94.9 (C-8), 156.6 (C-9), 105.6 (C-10), 120.6 (C-1'), 
130.9 (C-2'), 115.1 (C-3'), 160.2 (C-4'), 115.1 (C-5'), 130.9 (C-6'), 100.6 (C-1''), 74.1 
(C-2''), 76.4 (C-3''), 70.2 (C-4''), 74.5 (C-5''), 60.8 (C-6''), 98.3 (C-1'''), 69.9 (C-2'''), 
70.5 (C-3'''), 71.5 (C-4'''), 69.8 (C-5'''), 17.9 (C-6'''). 
 
Kaempferol-7-O-β-D-glucopyranoside (5)  




D  60.8 (c 0.2, MeOH)  




IR (KBr) vmax 3403, 2935, 1704, 1388, 1134 cm–1;  
1H NMR (800 MHz, DMSO-d6): δH 7.95 (2H, d, J = 8.0 Hz, H-2', 6'), 6.94 (2H, d, J 
= 8.0 Hz, H-3', 5'), 6.87 (1H, s, H-3), 6.82 (1H, br s, H-8), 6.44 (1H, br s, H-6), 5.06 
(1H, d, J = 7.3 Hz, H-1''), 3.70 (1H, d, J = 11.3 Hz, H-6''a), 3.48 (1H, dd, J = 11.0, 
5.6 Hz, H-6''b), 3.46 (1H, m, H-5''), 3.31 (1H, m, H-3''), 3.28 (1H, m, H-2''), 3.19 
(1H, m, H-4''); 
13C NMR (200 MHz, DMSO-d6): δC 164.2 (C-2), 103.0 (C-3), 182.0 (C-4), 161.4 
(C-5), 99.5 (C-6), 162.9 (C-7), 94.8 (C-8), 156.9 (C-9), 105.3 (C-10), 120.9 (C-1'), 
128.6 (C-2'), 116.0 (C-3'), 161.1 (C-4'), 116.0 (C-5'), 128.6 (C-6'), 99.8 (C-1''), 73.0 
(C-2''), 76.4 (C-3''), 69.5 (C-4''), 77.1 (C-5''), 60.5 (C-6''). 
 
Kaempferol-3-O-β-D-glucopyranoside (6)  




D  -64.2 (c 0.2, MeOH)  
IR (KBr) vmax 3401, 2971, 2923, 2371, 2320 cm–1  
1H NMR (600 MHz, DMSO-d6): δH 8.10 (2H, d, J = 8.6 Hz, H-2', 6'), 6.90 (2H, d, J 
= 8.6 Hz, H-3', 5'), 6.80 (1H, d, J = 1.6 Hz, H-8), 6.20 (1H, d, J = 1.6 Hz, H-6), 5.40 
(1H, d, J = 7.6 Hz, H-1''), 3.56 (1H, d, J = 11.0 Hz, H-6''a), 3.34 (1H, m, H-3''), 3.23 
(1H, m, H-4''), 3.22 (1H, m, H-6''b), 3.15 (1H, m, H-5''), 3.11 (1H, m, H-2''). 
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13C NMR (150 MHz, DMSO-d6): δC 156.0 (C-2), 133.4 (C-3), 177.5 (C-4), 160.9 
(C-5), 99.4 (C-6), 161.5 (C-7), 94.9 (C-8), 156.6 (C-9), 105.6 (C-10), 120.6 (C-1'), 
130.9 (C-2'), 115.1 (C-3'), 160.2 (C-4'), 115.1 (C-5'), 130.9 (C-6'), 100.6 (C-1''), 74.1 
(C-2''), 76.4 (C-3''), 70.2 (C-4''), 74.5 (C-5''), 60.8 (C-6''). 
 
Kaempferol 3-O-α-L-rhamnopyranosyl-(1→6)-β-D-glucopyranoside (7)  




D  56.7. (c 0.2, MeOH)  
UV (MeOH): λmax (log ε) 280 (3.7), 250 (3.8) nm  
IR (KBr) vmax 3400, 2972, 2942, 2371 cm–1  
1H NMR (400 MHz, DMSO-d6): δH 7.97 (2H, d, J = 8.8 Hz, H-2', 6'), 6.87 (2H, d, J 
= 8.8 Hz, H-3', 5'), 6.34 (1H, br s, H-8), 6.14 (1H, br s, H-6), 5.28 (1H, d, J = 7.7 Hz, 
H-1''), 4.37 (1H, s, H-1'''), 3.64 (1H, d, J = 11.0 Hz, H-6''a), 3.40 (1H, br s, H-2'''), 
3.24 (1H, m, H-3'''), 3.48 (1H, m, H-5''), 3.45 (1H, m, H-5'''), 3.34 (1H, m, H-3''), 
3.32 (1H, m, H-6''b), 3.27 (1H, m, H-2''), 3.46 (1H, m, H-3''), 3.19 (1H, m, H-4'''), 
0.98 (3H, d, J = 6.0 Hz, H-6'''). 
13C NMR (100 MHz, DMSO-d6): δC 156.9 (C-2), 133.2 (C-3), 177.4 (C-4), 161.2 
(C-5), 98.8 (C-6), 164.2 (C-7), 93.8 (C-8), 159.9 (C-9), 103.9 (C-10), 120.9 (C-1'), 
130.9 (C-2'), 115.1 (C-3'), 159.9 (C-4'), 115.1 (C-5'), 130.9 (C-6'), 101.3 (C-1''), 74.2 
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(C-2''), 76.3 (C-3''), 69.9 (C-4''), 75.7 (C-5''), 66.9 (C-6''), 100.8 (C-1'''), 70.3 (C-2'''), 
70.6 (C-3'''), 71.8 (C-4'''), 68.2 (C-5'''), 17.7 (C-6'''). 
 
Kaempferol 3-O-β-D-apiofuranosyl-7-O-β-D-glucopyranosyl-(1→3)- 
α-L-rhamnopyranoside (8)  




D  -60.3 (c 0.5, MeOH) 
HRESIMS m/z 725.1961 [M – H] – (calcd for 725.1935). 
UV (MeOH) λmax (log ε) 271 (3.80), 348 (3.30) nm  
IR νmax 3345, 1657, 1603, 1348, 1175, 1077 cm-1  
1H NMR data (800 MHz, DMSO-d6): See table 3  
13C NMR data (200 MHz, DMSO-d6): See table 4  
 
Quercetin 3-O-(6-O-E-feruloyl)-β-D-glucopyranosyl-7-O-α-L-rhamnopyranoside (9)  




D  -115.0 (c 0.5, MeOH)  
HRESIMS m/z 785.1964 [M – H] – (calcd for 785.1935). 
UV (MeOH) λmax (log ε) 265 (3.71), 326 (3.40) nm  
IR νmax 3304, 1656, 1598, 1446, 1286, 1181, 1085 cm-1  
1H NMR data (800 MHz, DMSO-d6): See table 1  
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D  -100.5 (c 0.2, MeOH)  
HRESIMS m/z 755.1830 [M - H]- (calcd for 755.1823). 
UV (MeOH): λmax (log ε) 266 (2.8), 326 (3.0) nm  
IR (KBr) vmax 3390, 2971, 1057, 1013 cm–1  
1H NMR (600 MHz, DMSO-d6): δH 7.59 (1H, d, J = 2.0 Hz, H-2'), 7.56 (1H, dd, J = 
8.4, 2.1 Hz, H-6'), 7.38 (2H, d, J = 8.6 Hz, H-2''', 6'''), 7.33 (1H, d, J = 15.5 Hz, H-
7'''), 6.83 (1H, d, J = 8.4 Hz, H-5'), 6.77 (2H, d, J = 8.5 Hz, H-3''', 5'''), 6.69 (1H, d, 
J = 2.0 Hz, H-8), 6.30 (1H, d, J = 2.0 Hz, H-6), 6.11 (1H, d, J = 15.5 Hz, H-8'''), 5.49 
(1H, d, J = 7.6 Hz, H-1''), 5.48 (1H, br s, H-1''''), 4.23 (1H, d, J = 10.3 Hz, H-6''a), 
4.11 (1H, dd, J = 11.0, 6.2 Hz, H-6''b), 3.84 (1H, br s, H-2''''), 3.61 (1H, m, H-3''''), 
3.40 (1H, m, H-2''), 3.38 (1H, m, H-4''), 3.30 (1H, m, H-5''), 3.28 (1H, m, H-3''), 3.28 
(1H, m, H-4''''), 3.28 (1H, m, H-3''), 3.22 (1H, m, H-5''''), 1.10 (3H, d, J = 6.1 Hz, H-
6''''). 
13C NMR (150 MHz, DMSO-d6): δC 156.7 (C-2), 133.3 (C-3), 177.5 (C-4), 160.7 
(C-5), 99.2 (C-6), 161.5 (C-7), 94.3 (C-8), 155.8 (C-9), 105.4 (C-10), 120.8 (C-1'), 
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116.2 (C-2'), 144.5 (C-3'), 148.7 (C-4'), 115.1 (C-5'), 121.6 (C-6'), 100.7 (C-1''), 74.3 
(C-2''), 76.2 (C-3''), 70.0 (C-4''), 73.9 (C-5''), 62.8 (C-6''), 124.9 (C-1'''), 130.1 (C-
2'''), 115.6 (C-3'''), 159.7 (C-4'''), 115.6 (C-5'''), 130.1 (C-6'''), 144.8 (C-7'''), 113.6 
(C-8'''), 166.2 (C-9'''), 98.3 (C-1''''), 70.0 (C-2''''), 70.2 (C-3''''), 71.5 (C-4''''), 69.8 (C-








D  -78.5 (c 0.5, MeOH)  
HRESIMS m/z 1077.3108 [M – H] – (calcd for 1077.3093). 
UV (MeOH) λmax 265 (3.50), 327 (3.38) nm  
IR νmax 3304, 1656, 1596, 1275, 1190, 1075, 1040 cm-1  
1H NMR data (800 MHz, DMSO-d6): See table 1  









D  -64.9 (c 0.5, MeOH)  
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HRESIMS m/z 931.2523 [M – H] – (calcd for 931.2514). 
UV (MeOH) λmax (log ε) 265 (3.65), 328 (3.58) nm  
IR νmax 3339, 1656, 1596, 1280, 1175, 1085 cm-1  
1H NMR data (800 MHz, DMSO-d6): See table 1  




Amorphous powder  
[]
25
D  -39.8 (c 0.5, MeOH)  
C39H46O20 
HRESIMS m/z 833.2513 [M – H] – (calcd for 833.2510). 
UV (MeOH) λmax (log ε) 223 (5.17), 269 (3.45), 340 (2.78) nm  
IR νmax 3424, 1658, 1613, 1495, 1459, 1352, 1256, 1133 cm-1  
1H NMR data (800 MHz, DMSO-d6): See table 3  
13C NMR data (200 MHz, DMSO-d6): See table 4  
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Table 1. 1H NMR spectroscopic data for compounds 1, 9, and 11-12 (in DMSO-d6). 
position 1a 9b 11b 12b 
6 6.33 (d, 2.0) 6.30 (d, 2.1) 6.32 (d, 2.0) 6.32 (d, 2.0) 
8 6.73 (d, 2.0) 6.69 (d, 2.0) 6.59 (d, 2.0) 6.76 (d, 2.0) 
2' 8.02 (d, 8.0) 7.58 (d, 2.1) 8.14 (d, 8.8) 8.09 (d, 8.9) 
3' 6.86 (d, 8.0)  6.87 (d, 8.8) 6.86 (d, 8.9) 
5' 6.86 (d, 8.0) 6.93 (d, 8.4) 6.87 (d, 8.8) 6.86 (d, 8.9) 
6' 8.02 (d, 8.0) 7.56 (dd, 8.4, 2.1) 8.14 (d, 8.8) 8.09 (d, 8.9) 
β-D-glcⅠ     
1'' 5.45 (d, 7.5) 5.49 (d, 7.6) 5.33 (d, 7.6) 5.41 (d, 7.6) 
2'' 3.25 (m) 3.39 (m) 3.26 (m) 3.26 (m) 
3'' 3.28 (m) 3.27 (m) 3.23 (m) 3.28 (m) 
4'' 3.23 (m) 3.39 (m) 3.15 (m) 3.23 (m) 
5'' 3.30 (m) 3.30 (m) 3.50 (m) 3.30 (m) 
6'' 
4.24  
(dd, 11.5, 2.0) 
4.12 (m) 
4.24 (d, 10.1) 
4.13 (dd, 11.9, 6.2) 
4.41 (dd, 11.8, 1.8) 
4.23 (dd, 11.9, 7.0) 
4.18 (dd, 11.2, 3.7) 
4.07 (dd, 11.3, 7.5) 
ferulic acid     
2''' 7.20 (d, 1.2) 7.20 (d, 1.8) 7.10 (d, 1.8) 7.18 (d, 1.8) 
5''' 6.78 (d, 8.0) 6.77 (d, 8.1) 6.60 (d, 8.1) 6.77 (d, 8.1) 
6''' 6.95 (dd, 8.0, 1.2) 6.94 (dd, 8.2, 1.8) 6.92 (dd, 8.1, 1.8) 6.95 (dd, 8.2, 1.8) 
7''' 7.35 (d, 15.5) 7.34 (d, 15.8) 7.49 (d, 15.8) 7.35 (d, 15.8) 
8''' 6.25 (d, 15.5) 6.24 (d, 15.8) 6.39 (d, 15.8) 6.24 (d, 15.8) 
OMe 3.81 (s, 3H) 3.81 (s, 3H) 3.68 (s, 3H) 3.79 (s, 3H) 
α-L- rhaⅠ     
1'''' 5.47 (br s) 5.46 (br s) 5.44 (d, 1.2) 5.48 (br s) 
2'''' 3.84 (br s) 3.84 (br s) 4.08 (br s) 4.11 (br s) 
3'''' 3.62 (dd, 9.0, 2.6) 3.61 (dd, 8.2, 3.2) 3.72 (dd, 9.0, 2.5) 3.75 (dd, 9.1, 3.1) 
4'''' 3.40 (m) 3.28 (m) 3.51 (m) 3.52 (m) 
5'''' 3.24 (m) 3.23 (m) 3.45 (m) 3.51 (m) 
6'''' 1.09 (d, 6.0, 3H) 1.09 (d, 6.2, 3H) 1.10 (d, 6.0, 3H) 1.11 (d, 6.1, 3H) 
β-D-glc Ⅱ     
1'''''   4.48 (d, 7.7) 4.48 (d, 7.6) 
2'''''   3.14 (m) 3.09 (m) 
3'''''   3.24 (m) 3.18 (m) 
4'''''   3.26 (m) 3.09 (m) 
5'''''   3.17 (m) 3.16 (m) 
6'''''   
3.71 (d, 10.0) 
3.25 (overlapped) 
3.70 (d, 11.0) 
3.45 (m) 
α-L- rha Ⅱ     
1''''''   4.38 (d, 1.2)  
2''''''   3.25 (br s)  
3''''''   3.41 (m)  
4''''''   3.06 (m)  
5''''''   3.09 (m)  
6''''''   0.97 (d, 6.0, 3H)  




Table 2. 13C NMR spectroscopic data for compounds 1, 9, and 11-12 (in DMSO-d6). 
a NMR 125 MHz; b NMR 200 MHz. 
position  1a 9b 11b 12b 
2 156.9 156.8 155.8 155.8 
3 133.4 133.4 133.6 133.5 
4 177.6 177.5 177.5 177.6 
5 160.8 160.8 160.7 160.7 
6 99.2 99.2 99.1 99.2 
7 161.5 161.5 161.1 161.2 
8 94.6 94.4 94.6 94.8 
9 155.9 155.8 157.3 156.9 
10 105.5 105.5 105.5 105.5 
1' 120.8 120.8 120.8 120.6 
2' 130.9 116.3 131.0 131.1 
3' 115.1 144.8 115.0 115.0 
4' 160.2 148.2 160.0 160.1 
5' 115.1 115.2 115.0 115.0 
6' 130.9 121.7 131.0 131.1 
β-D-glcⅠ     
1'' 101.0 100.8 101.5 101.6 
2'' 74.3 74.4 75.6 74.0 
3'' 76.2 76.3 76.0 76.2 
4'' 70.1 70.0 70.2 69.8 
5'' 74.1 74.0 74.1 74.1 
6'' 62.8 62.9 63.4 62.9 
ferulic acid     
1''' 125.5 125.5 125.3 125.5 
2''' 110.9 110.9 110.5 110.9 
3''' 147.8 147.8 147.6 147.8 
4''' 149.3 149.3 149.2 149.3 
5''' 115.4 115.4 115.1 115.4 
6''' 123.2 123.1 123.0 123.1 
7''' 144.9 144.9 145.2 145.0 
8''' 113.9 113.9 113.9 113.9 
9''' 166.3 166.3 166.6 166.2 
OMe 55.6 55.6 55.4 55.6 
α-L-rhaⅠ     
1'''' 98.3 98.4 97.9 98.1 
2'''' 69.8 69.8 69.2 68.2 
3'''' 70.2 70.2 81.2 80.7 
4'''' 71.6 71.6 70.1 70.5 
5'''' 69.8 69.8 69.6 68.9 
6'''' 17.9 17.8 17.8 17.8 
β-D-glcⅡ     
1'''''   105.0 104.6 
2'''''   73.8 72.9 
3'''''   76.4 76.2 
4'''''   70.5 69.5 
5'''''   74.2 76.7 
6'''''   66.7 60.9 
α-L-rhaⅡ     
1''''''   100.6  
2''''''   68.1  
3''''''   70.2  
4''''''   71.8  
5''''''   69.8  
6''''''   17.7  
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Table 3. 1H NMR spectroscopic data for compounds 8 and 13 (in DMSO-d6). 
position 8a position 13a 
3  3 7.14 (s) 
6 6.48 (d, 2.0) 6 6.39 (d, 2.0) 
8 6.86 (d, 2.0) 8 6.90 (d, 2.0) 
2' 7.98 (d, 8.0) 2' 7.32 (s) 
3' 6.91 (d, 8.0) 3'  
5' 6.91 (d, 8.0) 5'  
6' 7.98 (d, 8.0) 6' 7.32 (s) 
β-D-api  OMe 3.87 (s, 6H) 
1'' 5.74 (d, 2.1) Guaiacyl  
2'' 4.19 (d, 2.4) 1''  
3''  2'' 6.93 (br s) 
4'' 
3.60 (d, 9.3) 
3.49 (d, 9.3) 
3''  
5'' 
3.31 (d, 11.0) 
3.30 (d, 11.0) 
4''  
α-L- rha  5'' 6.69 (d, 8.1) 
1''' 5.59 (br s) 6'' 6.75 (dd, 8.0, 1.6) 
2''' 4.10 (br s) 7'' 4.79 (m) 
3''' 3.7 (dd, 8.7, 3.2) 8'' 4.37 (m) 
4''' 3.52 (m) 9'' 3.70 (m), 3.49 (m) 
5''' 3.51 (m) OMe 3.74 (s, 3H) 
6''' 1.14 (d, 6.0, 3H) β-D-glc  
β-D-glc  1''' 5.21 (d, 7.7) 
1'''' 4.48 (d, 7.7) 2''' 3.48 (m) 
2'''' 3.09 (m) 3''' 3.48 (m) 
3'''' 3.18 (m) 4''' 3.51 (m) 
4'''' 3.09 (m) 5''' 3.18 (m) 




3.68 (dd, 11.7, 1.9) 
3.43 (dd, 11.7, 5.7) 
α-L- rha  
  1'''' 5.12 (br s) 
  2'''' 3.69 (br s) 
  3'''' 3.34 (m) 
  4'''' 3.21 (m) 
  5'''' 3.77 (m) 
  6'''' 1.18 (d, 6.0, 3H) 









Table 4. 13C NMR spectroscopic data for compounds 8 and 13 (in DMSO-d6 ). 
position 8a position 13a 
2 157.3 2 163.9 
3 133.7 3 105.1 
4 177.0 4 182.2 
5 160.9 5 161.0 
6 99.5 6 99.6 
7 161.4 7 162.8 
8 94.8 8 95.0 
9 155.9 9 157.0 
10 105.7 10 105.6 
1' 120.5 1' 124.9 
2' 130.7 2' 104.3 
3' 115.5 3' 152.9 
4' 160.1 4' 139.7 
5' 115.5 5' 152.9 
6' 130.7 6' 104.3 
β-D-api  OMe 56.3 
1'' 109.2 Guaiacyl  
2'' 77.1 1'' 133.2 
3'' 79.4 2'' 110.9 
4'' 75.1 3'' 146.9 
5'' 62.7 4'' 145.4 
α-L- rha  5'' 114.7 
1''' 98.2 6'' 119.7 
2''' 68.9 7'' 72.1 
3''' 80.7 8'' 86.5 
4''' 70.5 9'' 60.3 
5''' 69.6 OMe 55.5 
6''' 17.8 β-D-glc  
β-D-glc  1''' 98.2 
1'''' 104.6 2''' 77.3 
2'''' 73.9 3''' 77.2 
3'''' 76.2 4''' 76.4 
4'''' 69.9 5''' 69.8 
5'''' 76.7 6''' 60.5 
6'''' 60.9 α-L- rha  
  1'''' 100.5 
  2'''' 70.4 
  3'''' 70.5 
  4'''' 71.8 
  5'''' 68.4 
  6'''' 18.0 
a NMR 200 MHz
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2.6. Computational chemistry for ECD calculation 
Turbomole at the def-SV(P) basis set for all atoms and the B3LYP functional 
was used to optimize the ground-state geometries with density functional theory 
(DFT) calculations. Harmonic frequency calculations were used to further confirm 
the ground states. The calculated ECD data corresponding to the optimized 
structures were obtained with TDDFT at the B3LYP functional. The ECD spectra 
were simulated by overlapping Gaussian functions for each transition (σ is the width 
of the band at 1/e height). ΔEi and Ri are the excitation energies and rotatory 
strengths for transition i, respectively. For this report, the value of σ was 0.10 eV.   










2 (2𝜎)2⁄ ] 
The Boltzmann-averaged computed ECD spectrum of the 5 representative 
conformers, corresponding 99% of the total Boltzmann distribution, was in good 
agreement with the experimental ECD spectrum of 13, which exhibited two strong 
positive cotton effects at 250 nm and 286 nm. These results suggested the absolute 
configuration of 13 was 7’’R,8’’R.  
 
2.7. Cell viability and triglyceride quantification in HepG2 cells  
To determine the cell viability, the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma, MO, USA) assay was performed. 
HepG2 cells were grown in 96-well plates with 5 × 103 cells per well for 1 day. Then, 
the isolated compounds were tested for their cytotoxicity against the HepG2 cell line 
using serum-free media. After 24 hours of incubation, 20 µL of the MTT solution (2 
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mg/mL) was added to each well, and the cultures were further incubated for 4 hours 
at 37°C. After removing the liquid, the formazan crystals were dissolved in 100 μL 
of dimethyl sulfoxide (DMSO). The absorbance of the purple formazan was 
measured at 550 nm using a microplate reader (VersaMax, PA, USA). Error bars 
were calculated as the mean ± SD of three independent experiments. HepG2 cells 
were grown in 12-well plates until 70-80% confluence and then the cells were 
induced into in vitro insulin-resistance models with high concentrations of glucose, 
free fatty acid, and insulin. Briefly, the cells were treated with various test 
compounds in the presence of a mixture of 0.2 mM palmitic acid (Sigma, MO, USA), 
30 mM glucose, 50 nM insulin and 0.1% bovine serum albumin (BSA) (Sigma, MO, 
USA) for 24 hours. Then, the cells were washed with phosphate-buffered saline 
(PBS), and the total intracellular lipids were extracted using cold 1% Triton X-100 
solution (Sigma, MO, USA) in PBS. The triglyceride levels were measured using a 
fluorometric triglyceride quantification kit (Cell Biolabs, Inc, CA, USA). Analyses 
were conducted following the manufacturer’s protocol with slight modifications. 
The fluorescence intensity was measured at ex/em = 530/585 nm using a 
fluorescence microplate reader (Spectra Max Gemini XPS, Molecular Devices, San 
Jose, CA, USA). Error bars were presented as the mean ± SD (n = 3).  
 
2.8. Oil-red O staining in HepG2 cells 
HepG2 cells were plated in 12-well plates until reaching 70-80% confluence. 
The cells were then treated with glucose, free fatty acid and insulin as above 
described. The insulin-resistant cells were exposed to the strong candidates and 
fenofibrate (Sigma, MO, USA) as a positive control. After 24 hours of incubation, 
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the cells were fixed with 5% formalin solution for 30 minutes and then incubated 
with oil-red O (Sigma, MO, USA) working solution for 15 minutes at room 
temperature. After that, the cells were washed once with 60% isopropanol, and three 
times with water. The nuclei were stained with hematoxylin solution (Sigma, Mo, 
USA) for 2 minutes at room temperature. In addition, another experiment was 
performed by staining the nuclei with 500 nM DAPI solution (Molecular Probes, OR, 
USA). The red oil droplets were visualized using fluorescence microscopy (Olympus 
ix70 Fluorescence Microscope, Olympus Corporation, Tokyo, Japan).  
 
2.9. Statistical analysis  
Data are presented by the mean ± SD of three independent experiments. For 
quantitative analysis of Western blotting, ImageJ software was applied. The one-way 
analysis of variance (ANOVA) was used to determine the significant differences 
between groups following Tukey’s or Duncan’s post hoc test as appropriate, which 
conducted in SPSS Statistics 23 (SPSS, Inc., Chicago, IL, USA). Statistical 




3. Results and discussion 
3.1. Molecular networking based grouping and identifying of chemical constituents 
Most major cluster consists of flavonoid glycosides and they are divided into two 
groups (Figure 6). In the first group, flavonoids were identified to possess only sugar 
moieties based on database analysis. However, in the second group, flavonoids were 
identified to contain not only sugar but also “prop-2-enoate” moiety. Based on this 
result, one group of flavonoid glycoside has potential to possess cinamoyl moiety. 
And this explains the inhibitory effects on lipid accumulation of S. angulatus since 
large numbers of researches have demonstrated the hepatic protective effect of 
cinamoyl group. Regarding the exact mass, the first decimal place was “2” in the 
first group and “1” in the second group since the mass defect of cinnamoyl group is 
greater than that of sugar moiety. For example, the mass defect of coumaric acid 
(C9H8O3;164.0473) is 0473, whereas, that of rhamnose (C6H12O5;164.0685) is 0685. 
The whole process of molecular networking was performed within a day and yielded 
information about compounds at a higher level of confidence.  
Library based identification was confirmed by UV spectrum analysis that the 
second flavonoid group contain cinnamoyl functional group. Molecular networking 
method not only dereplicates known molecules from complex compounds, it also 


















3.2. UV spectrum analysis 
The 70% ethanol extract of S. angulatus was analyzed by UV spectrum. As 
shown in figure 7, some flavonoid glycosides present their UV maxima at 350 nm, 
however, on the other hand, others present UV maxima at around 325 nm. This 
suggested that some flavonoid glycosides contain cinnamoyl group such as ferulic 
acid, coumaric acid or caffeic acid because the UV maxima at 325 nm is the 
indicative of ferulic acid. The UV maxima was shifted upfield among flavonoid 
glycosides with cinnamoyl group. This result was consistent with molecular 
networking data. 
Figure 7. UV spectrum of 70% ethanol extracted S. angulatus. 
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3.3. Elucidation of chemical structures of isolated compounds from S. angulatus 
(113) 
3.3.1. Compound 1 
Compound 1 was obtained as a yellowish powder with []
25
D  92.2 (c 0.5, MeOH). 
The molecular formula C37H38O18 was determined from the HRESIMS ion peak at 
m/z 769.2006 [M – H]– (calcd for C37H37O18, 769.1985). The IR spectrum of 
compound 1 suggested the presence of hydroxyl (3299 cm–1) and α,β-unsaturated 
carbonyl groups (1656 cm–1). The 1H and 13C NMR spectra of compound 1 displayed 
the presence of an A2B2 aromatic spin system at δH 8.02 (2H, d, J = 8.0 Hz, H-2', 6') 
and 6.86 (2H, d, J = 8.0 Hz, H-3', 5'), with corresponding carbons at δC 130.9 and 
115.1, respectively, which is indicative of the B ring of a flavonoid (Figures 8 and 
9). The meta-coupled protons of ring A resonated at δH 6.33 (1H, d, J = 2.0 Hz, H-6) 
and 6.73 (1H, d, J = 2.0 Hz, H-8). Two olefinic protons with a large coupling constant 
at δH 7.35 (1H, d, J = 15.5 Hz) and 6.25 (1H, d, J = 15.5 Hz) indicated a ferulic acid 
moiety in a trans-configuration. The 13C NMR spectrum presented signals for 37 
carbons, including two α,β-unsaturated carbonyl groups (δC 177.6 and 166.3), four 
olefinic carbon signals (δC 156.9-113.9), 18 aromatic carbon signals (δC 94.6-161.5), 
11 oxygenated carbons (δC 101.0-62.8), one methoxy carbon (δC 55.6) and one 
methyl carbon signal (δC 17.9). The above data suggested that compound 1 is a 
flavonoid glycoside with a ferulic acid moiety. Proton signals at δH 5.45 (1H, d, J = 
7.5 Hz) and 5.47 (1H, br s) were clearly indicative of anomeric protons, and the 
coupling constants suggested that a glucose is present as the β-isomer, and the other 
sugar, a rhamnose, is present as the α-isomer. Their presence was supported by the 
positive mass fragment ions at 625 [M – 146 (rhamnopyranosyl) + H]+ and 433 [M 
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– 176 (ferulic acid) – 162 (glucopyranosyl) + H]+. The HMBC correlation from an 
anomeric proton at δH 5.45 (1H, d, J = 7.5 Hz) to C-3 (δC 133.4) established the 
linkage of a glucopyranosyl moiety at C-3 of the aglycone. The anomeric proton of 
rhamnose (δH 5.47, 1H, br s) showed a HMBC correlation with C-7 (δC 161.5) of the 
aglycone (Figure 11). All the NMR data of compound 1 were similar to those of 
kaempferol 3-O-β-D-glucopyranosyl-7-O-α-L-rhamnopyranoside, which was 
isolated from Chenopodium murale (Gohar et al., 2000), except for the attachment 
of the ferulic acid moiety to C-6'' of the glucose in compound 1. The chemical shift 
of C-6'' in the glucose (δC 62.8) in compound 1 was shifted downfield compared to 
the C-6'' of the glucose (δC 61.0) in kaempferol 3-O-β-D-glucopyranosyl-7-O-α-L-
rhamnopyranoside. This was further confirmed by the HMBC correlation from H-6'' 
of the glucose (δH 4.24 and 4.12) to C-9''' of the ferulic acid moiety (δC 166.3) (Figure 
10). The position of methoxy and hydroxyl at ferulic acid was confirmed by ROE 
correlation between methoxy at δH 3.81 and ferulosy H-2 at δH 7.20 (d, J = 1.2 Hz). 







































































3.3.2. Compound 2 
Compound 2 was isolated as an amorphous powder with []
25
D  -67.8 (c 0.2, 
MeOH). Its molecular formula of 2 was identified as C36H36O17 based on an ion peak 
at m/z 739.1880 [M − H]− HRESIMS (calcd for C36H35O17, 739.1874). The 
calculation of IHD for this compound was recorded as nineteen indices. The 
characteristic difference is the replacement of the ferulic acid group in 1 [(δH 7.20, 
d, J = 1.2 Hz), (δH 6.95, dd, J = 8.0, 1.2 Hz), (δH 6.78, d, J = 8.0 Hz)] by the coumaric 
acid group in 2 [(δH 7.38, 2H, d, J = 8.0 Hz), (δH 6.77, 2H, d, J = 8.0 Hz)]. Two 
olefinic protons with a large coupling constant at δH 7.32 (1H, d, J = 15.5 Hz) and 
6.12 (1H, d, J = 15.5 Hz) indicated a ferulic acid moiety in a trans-configuration 
(Figure 12). With above observed spectroscopic data, compound 2 was determined 
















































3.3.3. Compound 3 
Compound 3, an amorphous powder with []
25
D  -80.5 (c 0.2, MeOH), was 
formulated as C33H40O19 based on the HRESIMS (m/z 739.2079 [M − H]− ;calcd for 
C33H39O19,  739.2085). The IHD of this compound was calculated as fourteen indices. 
The 1H and 13C NMR spectra of compound 3 presented an A2B2 aromatic spin system 
at δH 8.01 (2H, d, J = 8.7 Hz, H-2', 6') and 6.88 (2H, d, J = 8.7 Hz, H-3', 5'), with 
corresponding carbons at δC 130.9 and 115.1, respectively (Figure 13). Three 
anomeric protons were shown at δH 5.54 (s, H-1''''), 5.35 (d, J = 7.4 Hz, H-1'') and 
4.38 (br s, H-1''') indicating the presence of two rhamnose and one glucose in 
combination with the mass fragment. The major ion of compound 3 was m/z 739.2 
[M - H]-, and the ion produced by the loss of 292 Da (2 rhamnose) and 162 Da 
(glucose) suggested the existence of sugars. On the basis of above information, 
compound 3 was characterized to be kaempferol-3-O-(6-O-α-L-rhamnopyranosyl)-








































3.3.4. Compound 4 
Compound 4, an amorphous powder with []
25
D  50.6 (c 0.5, MeOH) gave a 
molecular formula of C27H30O15 from the HRESIMS ion peak at m/z 593.1502 [M – 
H]– (calcd for C27H29O15, 593.1506). All NMR data of compound 4 showed similar 
chemical shifts with compound 3 (Figure 14). The difference was the absence of 
rhamnose unit at C-6 of glucose, which was suggested by a upfield chemical shift of 
C-6 of glucose (δC 60.8; +5.9 ppm) compared to that of compound 3 (δC 66.7). The 
anomeric proton signal at δH 5.54 (1H, s) and δH 5.47 (1H, d, J = 7.3 Hz) suggested 
the existence of rhamnose and glucose, respectively. With above mentioned 
spectroscopic data, compound 4 was determined as kaempferol-3-O-β-D-
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3.3.5. Compound 5 
Compound 5 was obtained as an amorphous powder with []
25
D  60.8 (c 0.2, 
MeOH). The HRESIMS of this compound revealed an ion peak at m/z 431.0985 [M 
– H]– (calcd for C21H19O10, 431.0978). It suggested a molecular formula C21H20O10 
and indicated the presence of twelve IHD. The 1H NMR spectrum presented a singlet 
olefinic proton at δH 6.87 (1H, s, H-3). An A2B2 aromatic spin system at δH 7.95 (2H, 
d, J = 8.0 Hz, H-2', 6') and 6.94 (2H, d, J = 8.0 Hz, H-3', 5') were observed with 
corresponding carbons at δC 128.6 and 116.0, respectively (Figure 15). The H-6 (δH 
6.44, br s) was meta coupled with H-8 (δH 6.82, br s). The anomeric proton of glucose 
was observed at δH 5.06 (1H, d, J = 7.3 Hz). The chemical shift of C-7 in aglycone 
(δC 162.9) in compound 5 was shifted upfield compared to that of apigenin (δC 165.0) 
suggesting the attachment of glucose at C-7 of aglycone (Xu et al., 2009). The above 
spectroscopic data revealed that compound 5 was apigenin-7-O-β-D-








































3.3.6. Compound 6 
Compound 6, an amorphous powder with []
25
D  -64.2 (c 0.3, MeOH), was 
determined to have a molecular formula of C21H20O11, as suggested by the HRESIMS 
peaks at m/z 447.0932 [M – H]– (calcd for C21H19O11, 447.0927). According to NMR 
experiment, compound 6 clearly demonstrated a similar skeleton with compound 5 
except the glycosidic position. In compound 6, the olefinic proton of H-3 was not 
shown, indicating that C-3 was substituted by glucose (Figure 16). Thus, compound 

















3.3.7. Compound 7 
Compound 7 was isolated as an amorphous powder with []
25
D  56.7 (c 0.3, MeOH) 
and its molecular formula of C27H30O15 was analyzed based on the HRESIMS (m/z 
593.1511 [M - H]−, calcd for C27H29O15, 593.1506). The IDH for this compound was 
recorded as thirteen. Different to compound 6, one rhmanose was attached to H-6 of 
glucose. Two anomeric protons were shown at δH 5.28 (1H, d, J = 7.7 Hz) and δH 
4.37 (1H, s) with corresponding carbon signals at δC 101.3 and 100.8, respectively 
(Figure 17). The methyl group of rhamnose was indicated based on proton signal at 
δH 0.98 (3H, d, J = 6.0 Hz). With above mentioned spectroscopic data, compound 7 
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3.3.8. Compound 8 
Compound 8, a reddish gum with []
25
D  60.3 (c 0.5, MeOH), possessed the 
molecular formula C32H38O19 based on a HRESIMS peak at m/z 725.1961 [M – H] – 
(calcd for C32H37O19, 725.1935), which corresponds to 14 degrees of hydrogen 
deficiency. The IR spectrum of 8 showed characteristic peaks of hydroxyl (3345 cm–
1) and α,β-unsaturated carbonyl groups (1657 cm–1). The 1H and 13C NMR data for 
the aglycone of 8 revealed signals identical to those of 1 (Figure 18). Considering 
the proton NMR signals of the sugar moieties, three anomeric protons were observed 
at δH 5.74 (d, J = 2.1 Hz), 5.59 (br s) and 4.48 (d, J = 7.7 Hz). The anomeric proton 
signal at δH 5.74 (d, J = 2.1 Hz) was assigned to an apiose moiety by a series of 
pentose proton signals containing two methylene groups based on the COSY 
spectrum. The rhamnose anomeric proton at δH 5.59 (br s) and the glucose anomeric 
proton at δH 4.48 (d, J = 7.7 Hz) revealed α and β configurations, respectively. The 
identities of these fragments were supported by the positive mass fragment ions at 
595 [M – 132 (apiofuranosyl) + H]+, 565 [M – 162 (glucopyranosyl) + H]+, 433 [M 
– 162 (glucopyranosyl) – 132 (apiofuranosyl) + H]+. All the NMR data of compound 
8 were similar to those of kaempferol 3-O-β-D-apiofuranosyl-7-O-α-L-
rhamnopyranoside, which has been isolated from Lotus edulis (Spanou et al., 2008), 
except for the attachment of the glucopyranosyl unit to C-3''' of the rhamnose in 
compound 8, based on the HMBC correlation from H-3''' of rhamnose (δH 3.70) to 
C-1'''' of glucose (δC 104.6) (Figures 19-21). These results were further confirmed by 
the deshielding of the signal corresponding to C-3''' of rhamnose, which was shifted 
downfield by approximately 10 ppm compared to that of compound 1. Therefore, 
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Figure 18. 1H and 13C NMR spectra (DMSO-d6, 800/200 MHz) of compound 8 



































































3.3.9. Compound 9 
Compound 9 was isolated as a yellowish powder with a negative optical rotation 
([]
25
D115.0 (c 0.5, MeOH)). Its molecular formula was assigned as C37H38O19 based 
on the [M – H]– ion peak at m/z 785.1964 (calcd for C37H37O19, 785.1935) in the 
HRESIMS. Its IR spectrum showed bands indicative of a hydroxyl group (3304 cm–
1) and an α,β-unsaturated carbonyl group (1656 cm–1). The NMR spectra of 
compound 9 were similar to those of compound 1 except for the additional hydroxyl 
group on the B ring, indicating compound 9 possessed a quercetin aglycone instead 
of a kaempferol (Figure 22). The 1H and 13C NMR spectra of compound 9 displayed 
the presence of an ABX aromatic spin system at δH 7.58 (1H, d, J = 2.1 Hz, H-2'), 
6.93 (1H, d, J = 8.4 Hz, H-5') and 7.56 (1H, dd, J = 8.4, 2.1 Hz, H-6') with the 
corresponding carbons at δC 116.3 (C-2'), 115.2 (C-5') and 121.7 (C-6'), respectively, 
























Figure 22. 1H and 13C NMR spectra (DMSO-d6, 800/200 MHz) of compound 9
1’’’’
6’’’’  
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Figure 25. Key HMBC correlations (DMSO-d6, 800 MHz) of compound 9 
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3.3.10. Compound 10 
Compound 10, an amorphous powder with []
25
D  -100.5 (c 0.3, MeOH), was 
determined to have a molecular formula of C36H36O18, as suggested by the HRESIMS 
peaks at m/z 755.1830 [M – H]– (calcd for C36H35O18, 755.1823). The calculation of 
IHD for this compound was recorded as nineteen indices. The characteristic 
difference is the replacement of the ferulic acid group in 9 [(δH 7.20, d, J = 1.2 Hz), 
(δH 6.94, dd, J = 8.2, 1.8 Hz), (δH 6.77, d, J = 8.1 Hz)] by the coumaric acid group in 
10 [(δH 7.38, 2H, d, J = 8.6 Hz), (δH 6.77, 2H, d, J = 8.5 Hz)] (Figure 26). Two 
olefinic protons with a large coupling constant at δH 7.33 (1H, d, J = 15.5 Hz) and 
6.11 (1H, d, J = 15.5 Hz) indicated a ferulic acid moiety in a trans-configuration. 
With above observed spectroscopic data, compound 10 was determined to be 
quercetin 3-O-(6-O-E-coumaroyl)-β-D-glucopyranosyl-7-O-α-L-rhamnopyranoside 
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3.3.11. Compound 11 
Compound 11, a yellowish gum with []
25
D  78.5 (c 0.5, MeOH), possessed a 
molecular formula of C49H58O27 based on its HRESIMS peaks at m/z 1077.3108 [M 
– H]– (calcd for C49H57O27, 1077.3093). The IR spectrum of compound 11 indicated 
the presence of hydroxyl (3304 cm–1) and α,β-unsaturated carbonyl groups (1656 
cm–1). The spectroscopic data of 11 suggested that the structure of 11 was similar to 
that of 1. The difference was the attachment of a α-rhamnopyranosyl-(1→6)-O-β-D-
glucopyranosyl fragment to C-3'''' of the rhamnose (Rha Ⅰ) (δC 81.2). The 
glucopyranosyl unit (Glc Ⅱ) was suggested to attach to C-3'''' of the rhamnose (Rha 
Ⅰ) based on the HMBC correlation from H-1''''' (δH 4.48) to C-3'''' (δC 81.2). The 
HMBC correlation from H-1'''''' (δH 4.38) to C-6''''' (δC 66.7) suggested the linkage of 
the rhamnopyranosyl fragment (Rha Ⅱ) to the glucopyranosyl (Glc Ⅱ) (Figures 27-



















































































































3.3.12. Compound 12 
Compound 12 was obtained as a yellowish powder with a negative optical 
rotation ([]
25
D 64.9 (c 0.5, MeOH)). The molecular formula C43H48O23 was 
suggested by the HRESIMS peak at m/z 931.2523 [M – H]– (calcd for C43H47O23, 
931.2514). The IR spectrum of compound 12 indicated the presence of hydroxyl 
(3339 cm–1) and α,β-unsaturated carbonyl groups (1656 cm–1). The NMR spectra 
of compound 12 were similar to those of compound 1 except for a glucose attached 
to C-3'''' of the rhamnose (Figures 31 and 33). The glucopyranosyl unit (Glc Ⅱ) was 
found to be linked to C-3'''' of the rhamnose based on the HMBC correlation from 
H-1''''' (δH 4.48) to C-3'''' (δC 80.7), and this was confirmed by the deshielding of 
the signal corresponding to C-3'''' of the rhamnose, which was shifted downfield by 
approximately 10 ppm compared to that of compound 1 (Figure 32). Therefore, 

























Figure 31. 1H and 13C NMR spectra (DMSO-d6, 800/200 MHz) of compound 12 
7’’’ 















































3.3.13. Compound 13 
Compound 13 was isolated as an amorphous powder with a negative optical 
rotation []
25
D39.8 (c 0.5, MeOH). Its molecular formula was assigned as C39H46O20 
based on the [M – H]– ion peak at m/z 833.2513 (calcd for C39H45O20, 833.2510) in 
its HRESIMS. The IR spectrum showed the bands of a hydroxyl group (3424 cm–1) 
and α,β-unsaturated carbonyl groups (1658 cm–1). The 1H NMR spectrum of 13 
showed signals at δH 7.32 (2H, s), 7.14 (1H, s), 6.90 (1H, d, J = 2.0 Hz), 6.39 (1H, d, 
J = 2.0 Hz) and 3.87 (6H, s), indicating the presence of a tricin fragment with carbon 
signals at C-1' (δC 124.9), C-3' (δC 152.9) and C-5' (δC 152.9) (Figure 34). The other 
proton signals at δH 6.93 (1H, br s), 6.75 (1H, dd, J = 8.0, 1.6 Hz), 6.69 (1H, d, J = 
8.1 Hz), 4.79 (1H, m), 4.37 (1H, m), 3.74 (3H, s), 3.70 (1H, m) and 3.49 (1H, m) 
were predicted to be from a guaiacylglyceryl moiety. Two methoxy groups on the B 
ring resonated at δH 3.87, and this was confirmed by the HMBC correlations from δH 
3.87 to C-3' and 5' (δC 152.9). The guaiacylglyceryl moiety was confirmed to be 
attached to C-4' based on the HMBC correlation from H-8'' (δC 4.37) to C-4' (δC 
139.7) (Figure 35). The HMBC correlation from the anomeric proton at δH 5.21 (1H, 
d, J = 7.7 Hz) to C-7 (δC 162.8) suggested a glucopyranosyl moiety was attached at 
C-7. The other anomeric proton of the rhamnose (δH 5.12) showed an HMBC 
correlation to C-4''' of the glucose (δC 76.4). The NMR spectra of compound 13 were 
similar to those of tricin 4'-O-(threo-β-guaiacylglyceryl)ether-7-O-β-
glucopyranoside except for the attachment of the rhamnose to C-4''' of the glucose 
(Lee et al., 2015) (Figures 35-37). The relative configuration of compound 13 was 
determined based on the ROESY correlation between H-7'' (δH 4.79) and H-8'' (δH 
4.37), which suggested H-7'' and H-8'' were on the same face of the compound 
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(Figures 38 and 39). To determine the absolute configuration of compound 13, the 
ECD spectra for (7''R,8''R)-13 and (7''S,8''S)-13 were calculated using TDDFT at the 
B3LYP/def-SV(P) level. The conformational search of 7''R,8''R-13 using the 
molecular mechanics force field (MMFF) was performed, and the five lowest energy 
conformers corresponded to 99% of the total Boltzmann distribution (Table 5). The 
calculated ECD spectrum of 7''R,8''R-13 was in good agreement with the 
experimental ECD spectrum for compound 13 (Figure 40). Therefore, compound 13 
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Figure 40. Comparison of experimental and calculated ECD spectra of 13
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Table 5. Calculated DFT B3LYP/def-SV(P) free energies, population and theoretical averaged rotary strength values for the major conformers 









DFT B3LYP/def-SV(P) Gibbs free energies in kcal/mol relative to the absolute G value for the global minimum -720295,4490 kcal/mol. 
b
In 
percent from ΔG values at 298 K and 1 atm. pi =   (K=Boltzmann constant, T =  temperature, ε = Energy). 
c























Figure 41. Structures of isolated compounds from S. angulatus. 
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3.4. Inhibitory effects on hepatic lipid accumulation 
The reduction of hepatic lipid accumulation in this study was measured using 
HepG2 cells, which can be applied as a cell model for NAFLD. In the present study, 
we established a fatty liver cell model by incubating HepG2 cells in a high-glucose 
(30 mM glucose) and high-palmitic acid (0.2 mM palmitate) medium (Kuo et al., 
2012; Ding et al., 2014). To determine if the test concentrations of the isolated 
compounds were toxic, HepG2 cells were treated with 100 μM of compounds 1-13, 
and the cell viability was measured by the MTT assay. Since none of the compounds 
showed significant cytotoxicity at 100 μM, compounds 1-13 were tested at a 
concentration of 40 μM to determine their inhibitory effects on hepatic TG 
accumulation (Figure 42).  
 
 




Compounds 1-4, 6, and 11-13 inhibited the lipid accumulation induced by high 
concentrations of palmitic acid and glucose in HepG2 cells. Among the 13 tested 
compounds, compound 4 exhibited the greatest effect on TG accumulation in the cell 
(Figure 43). In addition, compounds 1, 3, 4, and 13 showed dose-dependent 




Figure 43. Inhibitory effects of the isolated compounds from S. angulatus on the 
high-glucose and high-palmitic acid induced lipid accumulation. HepG2 cells were 
treated with a mixture of palmitate (0.2 mM), glucose (30 mM), BSA (0.1%, w/v) 
and insulin (50 nM) in the absence or presence of compounds (1-13) at a 
concentration of 40 μM. Data are calculated as the mean ± SD (n=3) at * p < 0.05, 







Figure 44. HepG2 cells were treated with a mixture of palmitate (0.2 mM), glucose 
(30 mM), BSA (0.1%, w/v) and insulin (50 nM) in the absence or presence of several 
compounds (1, 3, 4, and 13) at various concentrations (10, 20, and 40 μM). After 24 
hours of incubation, the intracellular triglyceride levels were evaluated using a 
fluorometric triglyceride quantification kit. The results are expressed as the mean ± 
SD of three independent experiments; *p < 0.05, **p < 0.01, and ***p < 0.01 










The test compounds treated in HepG2 cells were analysed with an oil-red O 
staining assay using 40 μM fenofibrate, a drug clinically used to treat NAFLD, as a 
positive control. The cells were fixed and stained with the oil-red O solution after 1 
day of incubation and observed with a microscope to capture the image. Compounds 
1, 3, 4, 11, and 13 were found to significantly reduce lipid accumulation in HepG2 




Figure 45. Effects of strong candidates (1, 3, 4, 11, and 13) on the reduction of lipid 
accumulation in the insulin-resistance model using oil red O and hematoxylin 
staining method, original uncropped images. The images (1-10) are as follows; (1) 
ctrl without glucose; (2) ctrl with glucose (30 mM) only; (3) palmitate (0.2 mM) and 
glucose (30 mM); (4) mixture of palmitate (0.2 mM), glucose (30 mM) and insulin 
(50 nM); (5-10) mixture of palmitate (0.2 mM), glucose (30 mM) and insulin (50 

















Figure 46. Effects of compounds 1, 3, 4, 11, and 13 on reduction of lipid 
accumulation in the insulin-resistance model using the oil-red O staining method. 
HepG2 cells were exposed to the test compounds (40 μM), which dissolved in the 
media containing the palmitate and insulin as described in the experimental section. 
After 1 day of incubation, the cells were fixed and stained with the oil-red O and 
hematoxylin solution. Images were captured using an Olympus microscope. The 
images (1-10) are as follows; (1) ctrl without glucose; (2) ctrl with glucose (30 mM); 
(3) palmitate (0.2 mM) and glucose (30 mM); (4) mixture of palmitate (0.2 mM), 
glucose (30 mM) and insulin (50 nM); (5-10) mixture of palmitate (0.2 mM), glucose 
(30 mM) and insulin (50 nM) with fenofibrate (positive control) and tested 
compounds 1, 3, 4, 11, and 13 (40 μM), respectively. (C) The image on the right (1-
6) were magnified to see oil droplets in the cells. Treatment of compound 4 from S. 





Figure 47. Inhibitory effects of compounds 1, 3, 4, 11, and 13 on the palmitate and 
glucose-induced lipid accumulation using oil red O and DAPI staining method. 
Images were observed the red oil droplets and the nucleus using a fluorescence 
microscope. Each images (1-10) are as follows:(1) ctrl without glucose; (2) ctrl with 
glucose (30 mM) only; (3) palmitate (0.2 mM) and glucose (30 mM); (4) mixture of 
palmitate (0.2 mM), glucose (30 mM), and insulin (50 nM); (5-10) mixture of 
palmitate (0.2 mM), glucose (30 mM), and insulin (50 nM) with Fenofibrate, 







Among the eight bioactive compounds, seven compounds (1-4, 6, 11, and 12) 
are kaempferol glycosides and compound 13 is flavonolignan glycoside. These data 
are consistent with previously reported studies in which kaempferol glycoside 
decreased hepatic lipid content. Dietary kaempferol showed inhibitory effect on 
hepatic lipid content (Chang et al., 2011), and the kaempferol glycoside-rich fraction 
of soy bean leaves reduced lipid accumulation in liver by decreasing the expression 
of proliferator activated receptor (PPAR-γ) and sterol regulatory element binding 
protein (SREBP-1c) in animal test (Zang et al., 2015). PPAR-γ and SREBP-1c are 
important regulators of lipid metabolism in liver, and their levels are decreased when 
AMPK is activated (Ahmed and Byrne, 2007). Structure-activity relationship (SAR) 
analysis revealed that the presence of a cinnamoyl group enhanced the bioactivity. 
Kaempferol 3-O-β-D-glucopyranoside derivatives possessing either a coumaroyl or 
feruloyl group at C-6’’ of the glucose showed significant inhibitory activities (1, 2, 
11, and 12). These results are in good agreement with previous studies that 
kaempferol 3-O-(6-O-E-coumaroyl)-β-D-glucopyranoside showed strong anti-
diabetic activity (Ikechukwu and Ifeanyi, 2016; Zhang et al., 2014). However, few 
studies were reported on compounds with feruloyl moieties. In this research, we 
report their strong inhibitory effects on hepatic lipid accumulation. In addition, 
concerning their chemical structures, the structure of compound 13 is similar to that 
of silymarin flavonolignan glycosides, indicating its hepatoprotective effect (Cui et 





4. Conclusions   
A library of extracted natural materials (Korea Bioactive Natural Material Bank) 
have been screened to discover candidates for the treatment of non-alcoholic liver 
disease (NAFLD), and the 70% ethanol extract of S. angulatus was found to inhibit 
hepatic lipid accumulation. Herein, five previously undescribed flavonoid glycosides 
(1, 8, 9, 11, and 12) and one previously undescribed flavonolignan glycoside (13) 
along with seven known flavonoid glycosides (2-7, and 10) were isolated. To 
determine their inhibitory effects on hepatic lipid accumulation, we established a 
fatty liver cell model by incubating HepG2 cells with a high-glucose and high-
palmitic acid medium. Compounds 1-4, 6, and 11-13 were found to inhibit hepatic 
lipid accumulation. Especially compounds 1, 3, 4, and 13 showed strong inhibitory 
effects (10, 20, and 40 μM) on hepatic lipid accumulation in a dose-dependent 
manner. Compounds 1, 3, 4, 11, and 13 were also analysed for their inhibitory 
activities using oil-red O staining. These data demonstrated that kaempferol 
glycosides have inhibitory effects on fatty liver disease. Notably, kaempferol 3-O-β-
D-glucopyranoside derivatives possessing a cinnamoyl moiety showed significant 
inhibitory activities (1, 2, 11, and 12). This study suggests that the 70% EtOH extract 
of S. angulatus and flavonoid glycosides (1, 8, 9, 11, and 12) from this plant can 













Part 2. Eudesmane glycosides from Ambrosia artemisiifolia (Common 














1.1. Alzheimer’s disease 
Alzheimer’s disease (AD) is a neurodegenerative disorder featured by declines 
of judgement, cognition, memory, and behavior (Zhou et al., 2018). AD is the 
leading cause of dementia, becoming one of the largest public health concerns. 
Currently, 30 million people suffer from AD, and the World Health Organization has 
reported that the number of patients will triple over the next 20 years (Tangaro et al., 
2017). Owing to the steady growth of the aging population, an increasing prevalence 
of dementia is expected in both developing and developed countries. Accumulation 
of Aβ peptide into senile plaques has been considered one of the major causes of AD 
(Singh et al., 2018). Two types of Aβ peptides, Aβ40 and Aβ42, can exist outside as 
well as inside nerve cells. Aβ has been found to be a normal metabolite of amyloid 
precursor protein (APP), produced by the cleavage of APP by β-secretase and γ-
secretase (Habib et al., 2017). The senile plaque mainly consists of Aβ40 and Aβ42, 
which can produce several types of oligomeric structures such as protofibrils, fibrils 
and plaques according their extent of oligomerization (Palop et al., 2010). Several 
Aβs linked through hydrogen bonds form a protofibril, and aggregation of several 
protofibrils generates a fibril. Further aggregation of fibrils form plaques that are 
highly toxic to neurons (Takahashi et al., 2017). In AD, Aβ deposits as diffuse and 
compact plaques, and the latter consisting of Aβ fibrils are associated with a change 
of pathology in the brain and surrounding parenchyma, while diffuse plaques are not 
involved in degenerative changes (Baltes et al., 2011). Aβ aggregate-induced 
neurotoxicity, oxidative stress, and inflammatory reactions are related to the etiology 
of AD. Several studies have reported that the cytotoxic effect of Aβ is attributed to 
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its aggregation. Human amyloid precursor protein (hAPP) was transferred to mice 
and increased levels of Aβ altered the neuronal expression of synaptic activity-
regulated genes (Palop et al., 2007), and an Aβ-induced model of AD in rodents 
showed deficits in learning and memory abilities (Zhang et al., 2015). To date, the 
U.S. Food and Drug Administration (FDA) has approved only five drugs for AD: 
donepezil, galantamine, rivastigmine, tacrine, and memantine. However, these 
medications only temporarily improve cognition and delay the disease progression 















1.2. Ambrosia artemisiifolia 
The genus Ambrosia consists of approximately 50 species worldwide (The Plant 
List). A. artemisiifolia, native to the United States, spreads with competitive seeds 
and can grow rapidly; it is now recognized as an invasive species in Korea. Previous 
chemical studies of this plant have reported several sesquiterpenes, triterpenes, and 
















1.3. Mass defect filtering 
Discovery of previously undescribed compounds in natural products is becoming 
a challenge since large amount of known compounds have been already reported. 
Thus, the demands of developing strong analysis tool was increased and mass defect 
filtering was introduced in natural product field recently. Mass defect filtering was 
first developed as a metabolite analysis tool in pharmacokinetics field (Zhu et al., 
2006). Drug metabolite profiling using liquid chromatography/mass spectrometry is 
essential in pharmaceutical research. Metabolites can be anticipated using mass 
spectrometry since they are formed via well-known biotransformation such as 
hydroxylation or methylation. The concept of algorithm was that the difference of 
mass defect value between phase 1 and phase 2 metabolite fall within 50 mDa in 
pharmacokinetics field. The change in mass defect ranges from – 43 mDa (sulfation) 
to + 32 mDa (glucuronidation). For example, demethylation changes the mass defect 
by -23 mDA and hydroxylation affects +16 mDa. Thus, defining the mass defect 
ranging from – 23 m DA to + 16 mDa allows rapid detection of demethylated or 
hydroxylated metabolites from parent drug. The advantage and reproducibility of 
this method was proved in biological samples such as plasma, feces, bile and liver 
microsomes (Bateman et al., 2007).  
Mass defect filtering was applied to natural products field recently and facilitate 
to discover previously undescribed compounds. In the natural product field, the 
classification of natural products covers almost all types of organic molecules and 
each family possess different range of mass defect. Therefore, mass defect present 
strong evidence to classify compounds according to their family and this concept is 
also related to relative mass defect. The mass defect value of 1H is 0.0078 and that 
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of 16O is – 0.0051 (Table 6). Therefore, the higher the ratio of proton to oxygen, the 
higher the mass defect value and vice versa. Phenolic compounds such as flavonoid 
contain several benzene rings, thus the ratio of proton to oxygen tend to be low. 
However, at the same time, the ratio of proton to oxygen   is high in terpenes resulting 
in high value of mass defect. For example, as shown in figure 49, compound 1 is 
terpene and its nominal mass is 442 and compound 2 is flavonoid glycoside and its 
nominal mass is 448. The difference of nominal mass between the former and the 
latter is only 6 Da. However, they display significant different mass defect value. 



























Element Symbol Exact mass  Abundance Mass defect 
Hydrogen 1H 1.0078 99.19 0.0078 
Deuterium 2H 2.0141 0.015 0.0141 
Carbon 12 12C 12 98.90 0.0000 
Carbon 13 13C 13.0034 1.10 0.0034 
Nitrogen 14 14N 14.0030 99.63 0.0030 
Nitrogen 15 15N 15.0001 0.37 0.0001 
Oxygen 16 16O 15.9949 99.76 – 0.0051 
Oxygen 17 17O 16.9991 0.038 0.0001 
Oxygen 18 18O 17.9992 0.20 – 0.0008 
Fluorine 19F 18.9984 100.00 0.0016 
Sulfur 32 32S 31.9720 95.02 – 0.0280 
Sulfur 33 33S 32.9707 0.75 – 0.0293 
Sulfur 34 34S 33.9694 4.21 – 0.0306 
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This is because they contain significantly different ratio of proton to oxygen. 
Thus, limited range of nominal mass in combination with limited range of ratio of 
proton to oxygen allows to rapidly find certain derivatives.  
In this study, the chemical constituents of A. artemisiifolia were analyzed by 
high-resolution mass spectrometry to list up its chemical constituents. The RMD 
value (505) of some peaks (nominal mass:560) were determined as a terpene. This 
was well matched with previous studies that sesquiterpene lactones or eudesmane 
sesquiterpene glycosides were obtained from this plant (Jakupovic et al., 1988). To 
confirm their chemical structures in detail, NMR screening was performed to sub-
fractions. First, five fractions were prepared by column chromatography from 70% 
ethanol extract according to their polarity. Then, each five fractions were 
chromatographed by Sephadex-LH20 to remove phenolic compounds and finally 
terpene-rich sub-fractions were yielded. Five terpene rich fractions were analyzed by 
1H NMR spectrum. As shown in figure 50, two fractions presented HMG specific 
methylene peaks around δH 2.60 with overlapped resonances. Based on Scifinder 
database, only few sesquiterpene glycosides with HMG group was reported from 
nature. Using MDF method with well-designed parameter, the interferences were 









Figure 49. Chemical formula and exact mass of two different classes of compounds 
 
 
Figure 50.1H NMR spectrum of terpene-rich fraction 
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1.4. Purpose of research 
Three hundred extracts were selected from the KBNMB (Korea Bioactive 
Natural Material Bank) and screened for their inhibitory activities against Aβ-
induced NO production. As a result, 10 µg/mL of the ethyl acetate extract of A. 
artemisiifolia L. (Asteraceae) inhibited around 50% of Aβ-induced NO production. 
Thus, the purification of bioactive compounds from A. artemisiifolia was performed 





Scheme 3. The bio-guided isolation strategy of A. artemisiifolia. 
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2. Materials and methods 
2.1. Plant materials 
The whole plants of A. artemisiifolia was collected in September 2015 in Wonju, 
Gangwon Province, Korea. The sample was identified botanically by W. K. Oh. A 
voucher specimen (SNU2015-10) was deposited at the Medicinal Plant Garden of 
Seoul National University, Seoul, Korea. 
 
2.2. Chemicals, reagents, and chromatography 
Almost chemical and bioassay reagents, and experimental instruments in Part 2 
were used similarly to Part 1. However, there have other chemicals and equipment 
in this part, including:   
- MPLC (Biotage-Isolera One, Biotage, Charlotte, NC, USA) 
- C18 SNAP cartridges (KP-C18-HS; 120 g, Biotage) 
 - L-cystein (Tokyo chemical industry Co.Ltd, Tokyo, Japan) 
- phenyl isothiocyanate (Tokyo chemical industry Co.Ltd, Tokyo, Japan) 
- anhydrous pyridine (99.8%, Sigma-Aldrich, Missouri, USA) 
- Sep-pak plus long (Waters Associates, Milford, USA) 
 
2.3. Mass defect filtering 
Based on library dataset (Scifinder), eudesmane glycoside with HMG moiety or 
eudesmane glycoside containing two sugar groups may have a high possibility to be 
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a novel compound. To find certain derivatives, limited range of nominal mass and 
mass defect value were set. The difference of mass defect between HMG group and 
glucose was 10 mDa and the difference of mass defect among the sugar group is less 
than 10 mDa. (Figure 50). Thus, parameters were optimized according to these 
conditions. Nominal mass ranged from 520 to 610 and mass defect tolerance of ±10 
mDa was set.  
 
2.4. Extraction and isolation schemes 
The air-dried and powdered whole plants of A. artemisiifolia (4 kg) were 
extracted with 70% EtOH (20 L) three times (each 1 day) at room temperature. The 
extract (405 g) was partitioned with n-hexane (3 × 3 L), EtOAc (3 × 3 L), n-BuOH 
(3 × 3 L), and H2O. The EtOAc-soluble partition (96 g) was loaded onto a silica gel 
column (9.5 × 60 cm), eluted with n-hexane/acetone (1:0 to 0:1), to obtain seven 
fractions (A-G). Fraction A (21 g) was chromatographed via an open RP-18 column 
(2.5 × 40 cm) with MeOH/H2O (4:6 to 10:0) as solvents to give six sub-fractions. 
Fraction A.3 (100 mg) was crystallized from MeOH/H2O (6:4) to yield compound 
11 (24 mg). Fraction A.4 (90 mg) was crystallized from MeOH/H2O (6:4) to yield 
compound 12 (10 mg). Fraction A.6 (320 mg) was purified by semi-preparative 
HPLC (43% aqueous CH3CN, flow rate 3 mL/min) to isolate compounds 9 (6.0 mg; 
tR = 48.5 min) and 10 (5.5 mg; tR = 54.0 min). Fraction C (15 g) was subjected to 
passage over an open RP-18 column (4.5 × 40 cm) with MeOH/H2O (7:13 to 20:0) 
as solvents to give seven sub-fractions. Further purification of fraction C.5 (450 mg) 
using semi-preparative HPLC (26% aqueous CH3CN, flow rate 3 mL/min) yielded 
compound 8 (8.0 mg; tR = 28.2 min). Fraction D (10 g) was subjected to the open 
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RP-18 column (4.5 × 40 cm) separation using a CH3CN/H2O gradient (7:13 to 20:0), 
to give eight sub-fractions. Faction D.4 (800 mg) was subjected to Sephadex LH-20 
column chromatography with a MeOH/H2O system (17:3) to yield two sub-fractions. 
Compounds 2 (7.0 mg; tR = 42.0 min) and 7 (3.6 mg; tR = 17.0 min) were isolated 
from fraction D.4.1 using semi-preparative HPLC (26% aqueous CH3CN, flow rate 
3 mL/min). Fraction D.5 (430 mg) was purified using semi-preparative HPLC (26% 
aqueous CH3CN, flow rate 3 mL/min) to afford compound 3 (6.8 mg; tR = 35.5 min). 
After fraction D.6 (1.3 g) was separated by MPLC with a gradient system (5% 
CH3CN/H2O; 10 min/ 60% CH3CN/H2O; 60 min) to yield three fractions, subfraction 
D.6.1 (360 mg) was purified by semi-preparative HPLC (26% aqueous CH3CN, flow 
rate 3 mL/min) to furnish compound 4 (2.3 mg; tR = 65.2 min). Compounds 5 (2.4 
mg; tR = 44.8 min) and 6 (2.1 mg; tR = 52.0 min) were obtained by semi-preparative 
HPLC (26% aqueous CH3CN, flow rate 3 mL/min) from fraction D.6.2 (460 mg). 
Fraction D.6.3 (490 mg) was purified by semi-preparative HPLC with a gradient 
system (30% CH3CN/H2O; 8 min/ 45% CH3CN/H2O; 33 min) to provide compounds 
13 (6.0 mg; tR = 27.0 min) and 14 (5.0 mg; tR = 25.0 min). Fraction E (9 g) was 
separated using an open RP-18 column (4.5 × 40 cm; 150 μm particle size), with a 
MeOH/H2O (4:6 to 10:0) solvent system to produce ten sub-fractions. Fraction E.6 
(300 mg) was further purified by semi-preparative HPLC (26% aqueous CH3CN, 























2.5. Chemical and spectral properties of isolated compounds 
 
1α,6β,9β-Trihydroxy-5,10-bis-epi-eudesm-3-ene-9-O-[(S)-3′′-hydroxy-3′′-
methylglutaryl]-6-O-β-D-glucopyranoside (1)  




D  6.1 (c 0.5, MeOH)  
HRESIMS m/z 559.2773 [M – H] – (calcd for 559.2760) 
UV (MeOH) 𝜆max (log ε) 217 (3.16) nm  
IR (KBr) 𝜈max 3395, 2925, 1725, 1625 cm-1  
1H NMR data (400 MHz, DMSO-d6): See table 7  
13C NMR data (100 MHz, DMSO-d6): See table 8 
 
1α,6β,9β-Trihydroxy-5,10-bis-epi-eudesm-3-ene-1-O-[(S)-3′′-hydroxy-3′′-
methylglutaryl]-6-O-β-D-glucopyranoside (2)  




D  13.8 (c, 0.5, MeOH)  
HRESIMS m/z 559.2794 [M – H] – (calcd for 559.2760) 
UV (MeOH) 𝜆max (log ε) 217 (3.16) nm  
IR (KBr) 𝜈max 3399, 2926, 1720, 1455, 1083 cm-1  
1H NMR data (600 MHz, DMSO-d6): See table 7  




O-β-D-glucopyranoside (3)  




D  1.7 (c 0.5, MeOH)  
HRESIMS m/z 543.2820 [M – H] – (calcd for 543.2811). 
UV (MeOH) 𝜆max (log ε) 216 (3.17) nm  
IR (KBr) 𝜈max 3403, 2920, 1720, 1620 cm-1  
1H NMR data (600 MHz, DMSO-d6): See table 7  








D  31.8 (c 0.3, MeOH)  
HRESIMS m/z 601.2876 [M – H] – (calcd for 601.2866). 
UV (MeOH) 𝜆max (log ε) 217 (3.20) nm  
IR (KBr) 𝜈max 3389, 2913, 1731, 1615, 1435, 1085 cm-1  
1H NMR data (800 MHz, DMSO-d6): See table 7  









D  2.0 (c 0.5, MeOH)  
HRESIMS m/z 593.2812 [M + HCOO]– (calcd for 593.2815).  
UV (MeOH) 𝜆max (log ε) 217 (2.72) nm  
IR (KBr) 𝜈max: 3410, 2910, 1620 cm-1  
1H NMR data (800 MHz, DMSO-d6): See table 9 
13C NMR data (200 MHz, DMSO-d6): See table 10 
 
1α,6β,9β-Trihydroxy-5,10-bis-epi-eudesm-3-ene-6-O-β-D-glucopyranoside (6) 




D  1.7 (c 0.2, MeOH)  
HRESIMS m/z 461.2382 [M + HCOO] – (calcd for, 461.2392). 
UV (MeOH); 𝜆max (log ε) 217 (2.78) nm  
IR (KBr) 𝜈max 3413, 2909, 1615 cm-1  
1H NMR data (600 MHz, DMSO-d6): See table 9 





glucopyranoside (7)  




D  1.6 (c 0.5, MeOH)  
HRESIMS m/z 577.2850 [M + HCOO] – (calcd for 577.2866). 
UV (MeOH); 𝜆max (log ε) 217 (2.68) nm  
IR (KBr) 𝜈max 3403, 2911, 1630 cm-1  
1H NMR data (800 MHz, DMSO-d6): See table 9 
13C NMR data (200 MHz, DMSO-d6): See table 10 
 
1β,6α-Dihydroxyeudesman-4(15)-ene-1-O-β-D-glucopyranoside (8)  




D  -10.5 (c 0.1, MeOH)  
HRESIMS m/z 399.2360 [M - H]− (calcd for 399.2382). 
UV (MeOH): λmax (log ε) 215 (3.0) nm  
IR (KBr) vmax 3440, 2984, 1715, 1160, 1490 cm–1 
1H NMR (400 MHz, CDCl3): δH 4.95 (1H, s, H-15a), 4.74 (1H, s, H-15b), 4.29 (1H, 
d, J = 7.7 Hz, H-1'), 3.86 (1H, dd, J = 11.7, 1.8 Hz, H-6'a), 3.67 (1H, dd, J = 11.6, 
5.4 Hz, H-6'b), 3.63 (1H, m, H-6), 3.51 (1H, dd, J = 11.5, 4.4 Hz, H-1), 2.31 (1H, m, 
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H-11), 2.24 (1H, m, H-3a), 2.05 (1H, m, H-8a), 2.01 (1H, m, H-2a), 1.98 (1H, m, H-
3b), 1.76 (1H, d, J = 10.1 Hz, H-5), 1.54 (1H, m, H-2b), 1.50 (1H, m, H-9a), 1.23 
(1H, m, H-9b), 1.22 (1H, m, H-8b), 0.94 (3H, d, J = 7.1 Hz, H-12), 0.85 (3H, d, J = 
6.9 Hz, H-13), 0.74 (3H, s, H-14). 
 
3-Deacetoxylhymenolane (9)  




D  -40.2 (c 0.2, MeOH)  
HRESIMS m/z 351.1800 [M - H]− (calcd for 351.1807) 
UV (MeOH): λmax (log ε) 212 (3.7) nm  
IR (KBr) vmax 1730, 1380, 1053 cm–1 
1H NMR (600 MHz, CDCl3): δH 5.21 (1H, ddd, J = 8.0, 8.0, 4.8 Hz, H-3), 4.64 (1H, 
ddd, J = 11.7, 6.4, 4.3 Hz, H-8), 4.60 (1H, d, J = 7.5 Hz, H-4), 2.90 (1H, dq, J = 14.9, 
7.4 Hz, H-11), 2.68 (1H, m, H-7), 2.22 (1H, dt, J = 13.7, 4.7 Hz, H-2a), 2.15 (1H, m, 
H-9a), 2.06 (3H, s, AcO), 2.04 (3H, s, AcO), 2.04 (1H, m, H-10), 1.80 (1H, td, J = 
13.5, 4.7 Hz, H-2b), 1.72 (1H, m, H-9), 1.71 (1H, m, H-1), 1.56 (1H, dd, J = 14.7, 
2.1 Hz, H-6a), 1.09 (3H, d, J = 7.5 Hz, H-13), 1.09 (3H, s, H-15), 1.03 (3H, d, J = 
7.5 Hz, H-14). 
 
3α,4β-Diacetylhymenoratin (10)  
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D  34.8 (c 0.2, MeOH)  
HRESIMS m/z 349.1642 [M - H]− (calcd for 349.1651) 
UV (MeOH): λmax (log ε) 209 (3.3) nm  
IR (KBr) vmax 1735, 1640, 1452, 1053 cm–1;  
1H NMR (400 MHz, CDCl3): δH 6.25 (1H, d, J = 2.5 Hz, H-13a), 5.50 (1H, d, J = 2.5 
Hz, H-13b), 5.25 (1H, ddd, J = 7.9, 7.9, 4.8 Hz, H-3), 4.77 (1H, d, J = 7.5 Hz, H-4), 
4.68 (1H, ddd, J = 12.0, 7.8, 3.3 Hz, H-8), 3.21 (1H, m, H-7), 2.23 (1H, m, H-9a), 
2.18 (1H, m, H-2a), 2.12 (1H, m, H-10), 2.08 (3H, s, AcO), 2.05 (3H, s, AcO), 1.84 
(1H, m, H-2b), 1.78 (1H, m, H-9b), 1.71 (1H, m, H-1), 1.60 (1H, m, H-6a), 1.55 (1H, 
m, H-6b), 1.08 (3H, s, H-15), 1.06 (3H, d, J = 7.5 Hz, H-14). 
 
Ambrosic acid (11)  




D  55.8 (c 0.1, MeOH)  
HRESIMS m/z 263.1289 [M - H]− (calcd for 263.1283).     
UV (MeOH): λmax (log ε) 209 (3.0) nm  
115 
 
IR (KBr) vmax 3150, 3118, 1720, 1690 cm–1 
1H NMR (400 MHz, CDCl3): δH 6.41 (1H, br s, H-13a), 5.65 (1H, br s, H-13b), 4.37 
(1H, m, H-8), 2.94 (1H, br d, J = 11.9 Hz, H-7), 2.49 (1H, m, H-3a), 2.40 (1H, m, 
H-2b), 2.28 (1H, m, H-3b), 2.22 (1H, m, H-9a), 2.22 (1H, m, H-10), 2.13 (1H, m, H-
6b), 1.74 (1H, m, H-2b), 1.51 (1H, t, J = 13.0 Hz, H-6b), 1.22 (3H, d, J = 7.0 Hz, H-
14), 1.01 (3H, s, H-15). 
 
Cumambrin B (12)  




D  -30.4 (c 0.1, MeOH)  
HRESIMS m/z 263.1273 [M - H]− (calcd for 263.1283). 
UV (MeOH): λmax (log ε) 214 (3.4) nm  
IR (KBr) vmax 1760, 1635, 1435 cm–1  
1H NMR (400 MHz, CD3OD): δH 6.13 (1H, dd, J = 3.6, 0.9 Hz, H-13a), 6.01 (1H, 
dd, J = 3.3, 0.9 Hz, H-13b), 5.52 (1H, d, J = 1.6 Hz, H-3), 4.09 (1H, dd, J = 10.7, 9.4 
Hz, H-6), 3.89 (1H, m, H-8), 3.51 (1H, m, H-7), 2.72 (1H, dd, J = 10.6, 7.9 Hz, H-
1), 2.53 (1H, m, H-5), 2.26 (1H, dd, J = 15.7, 5.2 Hz, H-10), 2.21 (2H, m, H-2), 1.88 
(3H, d, J = 1.8 Hz, H-15), 1.79 (1H, d, J = 15.7, 1.6 Hz, H-9b), 1.23 (3H, s, H-14). 
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13C NMR (100 MHz, CD3OD): δC 172.2 (C-12), 144.5 (C-4), 141.7 (C-11), 126.9 
(C-3), 121.5 (C-13), 82.7 (C-6), 75.1 (C-10), 72.7 (C-8), 56.1 (C-1,5), 52.2 (C-7), 
42.5 (C-9), 34.6 (C-2), 32.9 (C-14), 18.1 (C-15). 
 
N1,N5,N10-Tri-p-coumaroylspermidine (13) 




D  80.5 (c 0.2, MeOH)  
HRESIMS m/z 582.2616 [M - H]− (calcd for 582.2604). 
UV (MeOH): λmax (log ε) 228 (2.5), 295 (3.4) nm  
IR (KBr) vmax 3394, 2960, 1650, 1448, 1210 cm–1  
1H NMR (600 MHz, CD3OD): δH 7.53/7.50 (1H, m, H-7''), 7.48/7.47 (1H, m, H-7'''), 
7.47/7.43 (1H, m, H-2'',6''), 7.44/7.43 (1H, m, H-7'), 7.39 (1H, m, H-2''',6'''), 
7.39/7.35 (1H, d, J = 8.5 Hz, H-2',6'), 6.85/6.81 (1H, d, J = 15.0 Hz, H-8''), 6.79 (1H, 
m, H-3''',5'''), 6.78/6.77 (1H, m, H-3',5'), 6.76/6.71 (2H, m, H-3'',5''), 6.42 (1H, d, J 
= 15.0 Hz, H-8'''), 6.40/6.37 (1H, d, J = 15.0 Hz, H-8'), 3.52 (4H, m, H-4, 6), 3.33 
(4H, m, H-2, 9), 1.92/1.85 (2H, quin, J = 6.0 Hz, H-3), 1.67 (2H, m, H-7), 1.60 (2H, 
m, H-8). 
13C NMR (150 MHz, CD3OD): δC 169.3 (C-9'''), 169.4/169.2 (C-9''), 169.3 (C-9'), 
160.7/160.5 (C-4',4'',4'''), 144.4 (C-7''), 142.2/141.9/141.8 (C-7',7'''), 130.9 (C-2'',6''), 
130.6 (C-2',6',2''',6'''), 127.9 (C-1''), 127.7 (C-1',1'''), 118.5 (C-8'''), 118.3/118.2 (C-
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8'), 116.8 (C-3',3'',3''',5',5'',5'''), 114.9 (C-8''), 49.0/47.6 (C-6), 47.0/45.7 (C-4), 
40.1/39.9 (C-9), 38.2/37.9 (C-2), 30.6/28.9 (C-3), 27.9/27.8 (C-8), 27.9/26.3 (C-7). 
 
N1,N5-Di-p-coumaroyl-N10-caffeoyl spermidine (14) 




D  67.9 (c 0.2, MeOH)  
HRESIMS m/z 598.2540 [M - H]− (calcd for C34H36N3O7, 598.2553). 
UV (MeOH): λmax (log ε) 228 (2.1), 295 (3.7) nm  
IR (KBr) vmax 3398, 2955, 1647, 1440, 1208 cm–1;  
1H NMR (500 MHz, CD3OD): δH 7.47/7.44 (2H, m, H-5'',9''), 7.46 (1H, m, H-3''), 
7.40/7.39 (2H, m, H-5',9' or H-5'',9'''), 7.38 (1H, m, H-3',3'''), 7.06 (1H, d, J = 15.0 
Hz, H-2''), 6.97 (1H, m, H-5',5'''), 6.82-6.70 (1H, m, H-5'or 5'''/6' or 6'''/8'/8'''/9' or 
9'''/6''/8''), 6.43/6.40/6.38/6.37 (1H, m, H-2',2'''), 3.55 (2H, m,  H-2, 9), 1.86 (2H, m, 








Table 7. 1H NMR spectroscopic data for compounds 1-4 (in DMSO-d6). 
position 1a 2b 3b 4c 
















(10.1, 7.1, 2.2) 
3 5.28, br s 5.28, br s 5.25, br s 5.28, br s 
4 - - - - 
5 3.01, br s 3.09, br s 2.57, m 3.03, br s 
6 4.43, m 4.46, m 4.41, dd 
(11.8, 4.8) 
4.40, m 
7 1.59, m 1.47, m 1.90, m 1.54, m 











(16.0, 8.0, 0.8) 




10 - - - - 
11 2.07, m 2.03, m 2.24, m 2.08, m 
12 1.04, d (6.5) 1.01, d (6.5) 1.05, d (6.0) 1.03, d (6.6) 
13 0.90, d (6.5) 0.93, d (6.5) 0.97, d (6.0) 0.91, d (6.6) 
14 0.92, s 0.97, s 0.99, s 0.92, s 
15 1.91, br s 1.88, br s 1.93, br s 1.89, br s 
glucose     
1’ 4.44, d (7.6) 4.43, d (7.7) 4.43, d (7.7) 4.43, d (7.8) 
2’ 3.20, m 3.20, m 3.22, m 3.24, m 
3’ 3.34, m 3.35, m 3.35, m 3.36, m 
4’ 3.31, m 3.33, m 3.23, m 3.41, dd 
(10.0, 6.9) 
5’ 3.22, m 3.24, m 3.21, m 3.21, m 















HMG     
2’’ 2.63, m 2.65, m 2.64, m 2.67, m 
4’’ 2.61, m 2.63, m 2.61, m 2.63, m 
6’’ 1.38, s 1.37, s 1.35, s 1.42, s 
AcO    2.04, s 




Table 8. 13C NMR spectroscopic data for compounds 1-4 (in DMSO-d6). 
position 1a 2b 3b 4c 
1 71.5 75.7 80.0 70.9 
2 33.4 31.1 30.6 33.4 
3 122.0 120.8 121.7 121.8 
4 137.0 136.4 138.1 136.8 
5 46.6 46.4 47.1 46.6 
6 77.6 77.9 75.2 78.0 
7 43.2 43.5 41.2 43.5 
8 29.1 32.0 22.1 29.4 
9 74.1 69.9 32.1 73.9 
10 42.7 42.0 40.1 42.6 
11 29.2 30.1 26.3 29.4 
12 22.7 22.2 24.1 22.6 
13 22.2 21.7 22.8 22.2 
14 12.7 13.9 12.7 12.8 
15 24.1 22.7 25.8 23.9 
glucose     
1’ 104.1 104.9 100.0 104.4 
2’ 75.4 75.6 75.7 75.1 
3’ 78.2 78.1 78.2 78.1 
4’ 71.7 71.5 72.2 71.9 
5’ 77.4 77.8 78.0 75.1 
6’ 62.8 62.6 63.1 65.2 
HMG     
1’’ 172.3 172.6 172.5 172.8 
2’’ 46.6 46.7 46.5 46.9 
3’’ 70.9 70.8 70.7 70.9 
4’’ 46.3 46.4 46.1 46.6 
5’’ 172.3 175.2 175.5 175.0 
6’’ 27.9 27.8 27.8 28.0 
AcO    172.7 
20.8 
a NMR 100 MHz; b NMR 150 MHz; c NMR 200 MHz 
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Table 9. 1H NMR spectroscopic data for compounds 5-7 (in DMSO-d6). 
position 5c 6b 7c 












3 5.27, br s 5.27, br s 5.25, br s 
5 2.97, br s 2.99, br s 2.45,br d (10.2) 
6 4.43, m 4.44, m 4.38, dd 
(11.1, 4.6) 
7 1.46, m 1.42, m 1.89, m 
8 2.25, m 
1.68, ddd 
(15.1, 9.7, 2.0) 
2.28, m 
1.62, ddd 
(15.0, 9.8, 1.5) 
1.68, m 
1.80, m 
9 4.07, dd 
(7.3, 2.0) 
3.93, d (6.5) 1.57, m, 
1.31, td (13.6, 4.8) 
11 2.04, m 1.99, m 2.21, m 
12 0.94, d (6.7) 0.93, d (6.5) 0.99, d (6.8) 
13 1.02, d (6.6) 1.01, d (6.5) 1.07, d (6.8) 
14 0.91, s 0.83, s 0.87, s 
15 1.86, br s 1.85, br s 1.91, br s 
 arabinose glucose glucose 
1’ 4.37, d (7.6) 4.43, d (7.8) 4.43, d (7.7) 
2’ 3.81, m 3.17, m 3.21, m 
3’ 3.45, m 3.32, m 3.31, m 
4’ 3.32, m 3.32, m 3.27, m 
5’ 3.22, m 
3.15, m 
3.23, m 3.31, m 








 glucose  apiofuranose 
1’’ 4.45, d (7.6)  4.99, d (1.9) 
2’’ 3.17, m  3.88, d (1.8) 
3’’ 3.32, m  - 
4’’ 3.54, m  3.90, d (9.6) 
3.74, d (9.6) 
5’’ 3.24, m  3.58, s 




b NMR 600 MHz; c NMR 800 MHz 
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Table 10. 13C NMR spectroscopic data for compounds 5-7 (in DMSO-d6). 
position 5c 6b 7c 
1 82.1 71.6 77.3 
2 33.0 33.9 33.5 
3 121,7 121.5 122.5 
4 136.4 136.1 137.8 
5 46.2 46.6 47.3 
6 77.8 78.4 75.7 
7 43.6 43.7 41.6 
8 31.8 32.4 22.7 
9 70.2 70.3 32.1 
10 43.0 42.9 41.3 
11 29.9 30.2 26.5 
12 21.9 21.6 22.9 
13 22.3 22.1 24.1 
14 13.7 12.7 11.6 
15 26.1 22.6 26.1 
 arabinose glucose glucose 
1’ 105.9 104.9 100.0 
2’ 77.9 75.6 75.7 
3’ 75.5 78.1 78.2 
4’ 71.2 71.4 71.9 
5’ 70.0 77.8 76.8 
6’  62.6 68.2 
 glucose  apiofuranose 
1’’ 104.1  110.7 
2’’ 75.7  78.1 
3’’ 78.2  80.6 
4’’ 71.6  75.0 
5’’ 78.1  66.0 
6’’ 62.7   
b NMR 150 MHz; c NMR 200 MHz 
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2.6. Determination of the absolute configuration of sugars in compounds 5 and 7. 
    Compound 5 (0.9 mg) was hydrolyzed with 1 N HCl (1.0 mL) for 8 h at room 
temperature and compound 7 (0.9 mg) was hydrolyzed by 2 N HCl (1.0 mL) at 60 °C 
for 3 h. For each, after neutralization with Na2CO3 and concentration under reduced 
pressure, L-cysteine methyl ester hydrochloride in anhydrous pyridine (0.5 mg) was 
added, followed by heating for 1 h at 60 °C. Then, phenyl isothiocyanate (0.1 mL) 
was added, and the mixture was heated at 60 °C for 1 h. The final solution was 
analyzed by LC-MS (column: an INNO C18 column, 5 m, 120 Å , 4.6 × 250 mm; 
10-80% CH3CN/H2O, 0-30 min; detection wavelength: 203 nm; flow rate: 1.0 
mL/min). The retention times of the sugar derivatives were established by 
comparison with those of the derivatives of commercial L-arabinose (tR = 7.21 min), 
D-glucose (tR = 6.95 min), and D-apiose (tR = 7.90 min), respectively. Thus, it was 
determined to be the D-configuration of the glucose and apiose and the L-
configuration of arabinose moieties in compounds 5 and 7. 
 
2.7. Absolute configuration of HMG (3-hydroxy-3-methylglutaryl) in compound 1.  
(S)-1-Phenylethylamine (1.52 μL, 12.0 μmol), benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP, Sigma-Aldrich) (4.6 
mg, 9.2 μmol), Et3N (2.28 μL, 18.0 μmol), and hydroxybenzotriazole (HOBt, Sigma-
Aldrich) (1.6 mg, 12.0 μmol) were mixed with a solution containing compound 1 
(3.9 mg, 6.0 μmol) and then cooled in ice bath. The mixture was stirred at 25 °C for 
9 h, and dilute aqueous HCl was added to quench the reaction. The mixture was 
partitioned with EtOAc and consequently separated over a silica gel (CHCl3/MeOH, 
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19:1, 10:1, and 1:1) to yield 1a (3.0 mg). The ESIMS analysis showed a [M + 
HCOO]– peak at m/z 708. LiBH4 (2.2 mg, 67.5 μmol) was mixed with a 1a-
containing solution (3.0 mg, 4.5 μmol) and THF (0.3 mL). After 24 h of stirring at 
25 °C, the solution was mixed with 10 µL of HCl (0.2 N) and then partitioned with 
EtOAc. The resulting extract was separated over silica gel (CHCl3/MeOH, 19:1, 10:1, 
and 1:1) and yielded a colorless oil. For acetylation, the sample was stirred at 25 °C 
for 24 h with Ac2O (2.1 μL, 22.5 μmol) in pyridine (30 μL), and diluted using H2O. 
The mixture was partitioned with EtOAc to yield 1b (0.5 mg). 
3(R)-5-O-Acetyl-1-[(S)-phenylethyl]-mevalonamide (1b): colorless oil; 1H 
NMR (CDCl3, 600 MHz) δH 7.26-7.36 (5H, m, Ph), 5.15 (1H, q, J = 7.1 Hz, H-1'), 
4.23 (2H, m, H-5), 2.41, 2.29 (each 1H, d, J = 14.8 Hz, H-2), 2.04 (3H, s, Ac), 1.85-
1.87 (2H, m, H-4), 1.51 (3H, d, J = 6.9 Hz, H-2'), 1.24 (3H, s, H-6); ESIMS m/z 
294.2 [M + H]+.  
 
2.8. Computational chemistry for ECD calculation.  
Conformational analysis was performed by means of the CONFLEX software 
using the MMFF94 force field. Geometry optimization [B3LYP/6-31G(d) in vacuo] 
and TDDFT calculations were carried out with Turbomole (Yang et al., 2015). 
Boltzman distributions were calculated from the B3LYP/6-31g(d) energy and the 
ECD spectra were generated as the sum of Gaussian. Ri and ΔEi represented the 
strengths of rotation, and the value of σ in the equation was 0.10 eV.   










2 (2𝜎)2⁄ ] 
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Each major conformer of 1-4 occupied 99% of the Boltzmann population and the 
spectra of each simulation matched well to the corresponding experimental one. This 
suggested that the absolute configurations for the aglycones were 
1S,5R,6R,7S,9S,10S (1 and 4), 1S,5R,6R,7S,9S,10R (2), and 1R,5S,6S,7R,10R (3), 
respectively.  
 
2.9. Hydrolysis of 1-3, 5, and 7.  
Hydrolysis of compounds 1-3 and 5 were performed to confirm the configuration 
of C-1. Acid hydrolysis of 1 by stirring at room temperature for 4 h in 3 mL of 1 N 
HCl yielded 1c. Acid hydrolysis of compounds 2, 5, and 7 by stirring for 8 h in 3 mL 
of 1 N HCl yielded 2a, 5a, and 7a, respectively. Alkaline hydrolysis of compound 3 
by stirring for 24 h in 3 mL of 3 N KOH yielded 3a  
 
1β,6α-Dihydroxy-7-epi-eudesm-3-ene-6-O-β-D-glucopyranoside (3a). 1H 
NMR (CD3OD, 800 MHz) δH 5.25 (m, H-3), 4.45 (d, J = 7.6 Hz, H-1'), 4.39 (dd, J = 
11.2, 4.5 Hz, H-6), 3.77 (m, H-6a'), 3.68 (dd, J = 11.9, 4.1 Hz, H-6b'), 3.49 (dd, J = 
9.8, 6.7 Hz, H-1), 3.33 (m, H-3'), 3.30 (m, H-5'), 3.26 (m, H-4'), 3.22 (m, H-2'), 2.45 
(m, H-5), 2.24 (m, H-2a), 2.21 (m, H-11), 1.94 (m, H-2b), 1.91 (br s, H3-15), 1.86 
(m, H-7), 1.80 (m, H-8a), 1.68 (m, H-8b), 1.57 (m, H-9a), 1.31 (td, J = 13.6, 4.8 Hz, 
H-9b), 1.07 (d, J = 6.8 Hz, H3-13), 0.99 (d, J = 6.8 Hz, H3-12), 0.87 (s, H3-14); 13C 
NMR (CD3OD, 200 MHz) δC 137.8 (C-4), 122.5 (C-3), 100.0 (C-1'), 78.2 (C-3'), 
77.9 (C-5'), 77.3 (C-1), 75.7 (C-6), 75.7 (C-2'), 72.1 (C-4'), 63.0 (C-6'), 47.3 (C-5), 
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41.6 (C-7), 41.3 (C-10), 33.5 (C-2), 32.1 (C-9), 26.4 (C-11), 26.0 (C-15), 24.1 (C-
13), 22.9 (C-12), 22.7 (C-8), 11.4 (C-14); ESIMS m/z 445 [M + HCOO]-. 
 
2.10. Measurement of cell viability.  
The cell cytotoxicity was evaluated using the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) reagent (Sigma). Briefly, HT22 cells, 
immortalized mouse hippocampal neuronal cells, were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) (HyClone, Logan, UT, USA) containing 10% 
fetal bovine serum (FBS) (HyClone), 100 U/mL penicillin and 100 μg/mL 
streptomycin. Then, 96-well plates were used to seed cells (4000 cells/well) and 
incubated for 24 h. Test compounds were dissolved in dimethyl sulfoxide (DMSO) 
(Junsei, Japan) and diluted in serum-free medium [final DMSO concentration 0.1-
0.2 % (v/v)]. After 24 h of incubation, a 2 mg/mL MTT solution (20 μL) was added 
to each well and incubation was continued for 4 h in the dark. The supernatants were 
removed and formazan crystals were dissolved in DMSO. The absorbance was 
recorded with a microplate reader (VersaMax, PA, USA) at 550 nm.  
 
2.11. Cytotoxicity assay and fluorescence images of Aβ42-transfected HT22 cells. 
    HT22 cells were seeded into 96-well plates at 4000 cells/well and incubated for 
2-3 h at 37 °C under a 5% CO2 atmosphere. The cells in each well were transfected 
with 0.2 μg of pEGFP-C1/Aβ42 plasmid (a gift from Professor Junsoo Park, Yonsei 
University, Korea) with Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, 
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USA). After 10 h of transfection, the compounds dissolved in the medium and used 
to treat the cells. Afterwards, the cells were continually incubated for 24 h and 20 μL 
of MTT solution (2 mg/mL) were added. Similarly, HT22 cells were grown on 
sterilized glass coverslips and transfected with Aβ42 plasmid for 10 h. The cells were 
replaced with fresh medium containing 2% FBS with or without test compounds. 
After 24 h of incubation, the cells were washed once with phosphate-buffered saline 
(PBS) (Takara, Japan). Fluorescence microscopy was applied to capture both 
fluorescence and bright-field images (Olympus IX70, Olympus Corporation, Tokyo, 
Japan).     
 
2.12. Flow cytometry analysis of fluorescence intensity.  
For flow-cytometry analysis, the HT22 cells were seeded into 6-well plates for 
2-3 h. After being transfected with the Aβ42 plasmid for 10 h, the cells were exposed 
to the test compounds using medium supplemented with 2% FBS. The cells were 
then incubated for 24 h at 37 °C under a 5% CO2 atmosphere. Afterwards, all cells 
(both dead and live) were collected by a trypsinization method. The cells were 
resuspended in PBS and a flow cytometer (BD, FACS Calibur, San Jose, CA, USA) 
was used for analysis. For each test compound, at least 10,000 events were counted 
and data were calculated using gates. 
 
2.13. Statistical analysis.  
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Data was processed through variance analysis (ANOVA) to determine the 
significance of differences between each group followed by Tukey’s 
or Duncan’s post hoc test. A p-value < 0.05 was taken as a significant difference (* 


















3. Results and discussion 
3.1. Mass defect filtering 
The chemical identification of 70% ethanol extracted A. artemisiifolia was 
carried out using ultra-high-pressure liquid chromatography-quadrupole time-of-
flight tandem mass spectrometry (UHPLC-qTOF-MS/MS). As mentioned above, 
only few eudesmane glycosides possessing either HMG group or two sugar groups 
were reported from nature. Thus, MDF was performed to find targeted peaks. In the 
process of setting the mass defect parameter, it was discovered that the chemical 
formula of HMG (C6H8O4) was similar with that of glucose (C6H10O5). Thus the 













Figure 51. Chemical formula and exact mass of targeted compounds 
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This tendency also applies to sugar groups. Each sugar shares similar chemical 
formula (glucose: C6H10O5, rhamnose: C6H10O4, arabinose: C5H8O4) resulting in 
similar mass defect value. Therefore, in a range from 520 to 610 with the mass defect 
tolerance of ±10 mDa, eudesmane glycosides possessing either HMG group or two 
sugar groups were selected.  
As a result, targeted peaks (compounds 1-5 and 7) were shown and their exact 
mass suggested their novelty. (Figure 52 and Tables 7-10). The targeted peaks were 
difficult to identify in total extraction, however, they were shown clearly after mass 
defect filtering. This work demonstrated the feasibility of the mass defect filtering 
method for picking new compounds in complex chromatography. It eliminated the 
background noise as well as presenting certain targeted derivatives. 
 
 
Figure 52. Mass defect filtered chromatogram of A. artemissifolia. 
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3.2. Structural elucidation of isolated compounds (1-14) 
3.2.1. Compound 1 
Compound 1 was isolated as an amorphous powder with []
25
D  6.1 (c 0.5, MeOH). 
The HRESIMS data (m/z 559.2773 [M – H]–, calcd for C27H43O12, 559.2760) 
established the molecular formula as C27H44O12. The IR bands at 3395, 1725, and 
1625 cm−1 were indicative of hydroxy, carbonyl, and olefinic groups. The 1H NMR 
data showed an olefinic proton at δH 5.28 (1H, br s), an allylic methyl group at δH 
1.91 (3H, br s), a singlet methyl group at δH 0.92 (3H, s), and two doublet methyl 
moieties [δH 1.04 (3H, d, J = 6.5 Hz) and 0.90 (3H, d, J = 6.5 Hz)], suggesting the 
occurrence of an eudesmane-type sesquiterpene, with the corresponding carbon 
signals at C-3 (δC 122.0), C-4 (δC 137.0), C-12 (δC 22.7), C-13 (δC 22.2), C-14 (δC 
12.7), and C-15 (δC 24.1) (Figure 53). The COSY correlations between H-1/H-2, H-
2/H-3, H-3/H-5, H-5/H-6, H-6/H-7, H-7/H-8, H-8/H-9, and H-9/H-14 together with 
HMBC correlation between H-1/C-14 confirmed the A/B ring system of an 
eudesmane sesquiterpene (Figures 56-57). The HMBC correlations from two doublet 
methyl groups to one tertiary carbon (H3-12/C-11 and H3-13/C-11) indicated an 
isopropyl group, and its position was confirmed by the HMBC correlation from H-
11 (δH 2.07) to C-7 (δC 43.2). Other proton signals of two pairs of methylene protons 
[δH 2.63 (2H, m) and 2.61 (2H, m)] and a singlet methyl group at δH 1.38 (3H, s) 
were predicted to be from a 3''-hydroxy-3''-methylglutaryl (HMG) moiety, with 
corresponding carbon signals at C-2'' (δC 46.6), C-4'' (δC 46.3), and C-6'' (δC 27.9). 
The chemical structure of compound 1 is similar to 1α-cinnamolyoxy-6β-hydroxy-
5,10-bis-epi-eudesm-3-ene isolated from A. artemisioides but additionally showed 
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the presence of a HMG moiety and a glucopyranosyl group along with the absence 
of a cinnamoyl group (Jakupovic et al., 1988). The linkage of a HMG moiety was 
determined at C-9 by the HMBC correlation from H-9 (δH 4.95) to C-1'' (δC 172.3) 
(Figure 54). The glycosylation position was established by HMBC cross-peaks 
between H-1' (δH 4.44) and C-6 (δC 77.6) (Figure 55). A concerted method that 
consists of the process of amination, reduction, and acetylation revealed the absolute 
configuration of the HMG group (Eom et al., 2016). (S)-1-Phenylethylamine was 
used to obtain the aminated compound 1a. Subsequently, compound 1a was reduced 
with LiBH4, and then acetylated with Ac2O to give 5-O-acetyl-1-[(S)-
phenylethyl]mevalonamide (1b) (Figure 60). The proton NMR information of 1b 
was consistent with (3R)-5-O-acetyl-1-[(S)-phenylethyl]mevalonamide, but not 
(3S)-5-O-acetyl-1-[(S)-phenylethyl]mevalonamide (Kamo et al., 2004) (Figure 61). 
The relative configuration of the aglycone of 1 was determined by interpretation of 
its NOESY data. In the NOESY spectrum, H-1 (δH 3.93) correlated with H-5 (δH 
3.01), whereas H-14 (δH 0.92) was correlated to H-6 (δH 4.43), H-7 (δH 1.59), and H-
9 (δH 4.95), as shown in Figure 58. With respect to the 13C NMR chemical shifts, a 
significant difference was suggested for C-1 according to the configuration of the 
hydroxy group found in previous research for eudesmane-type sesquiterpenes (Hu et 
al., 2001; Chernenko et al., 1994; Zhang et al., 2003; Mahmoud et al., 1997). The 
chemical shift of C-1 (δC 72.1) with an α-oriented hydroxy group is relatively upfield 
compared to C-1 (δC 79.4) with a β-oriented hydroxy group (Hu et al., 2001; 
Chernenko et al., 1994). The HMG moiety of 1 was removed by acid hydrolysis to 
yield 1c and the similar carbon chemical shift of C-1 (δC 71.7) with that of previous 
reported compounds (δC 72.1) with an α-oriented hydroxy group confirmed the 
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configuration at C-1. To define the absolute configuration of 1, ECD calculations 
were performed for (1S,5R,6R,7S,9S,10S)-1 and (1R,5S,6S,7R,9R,10R)-1 by TDDFT 
at the B3LYP/def-SV(P) level (Table 11). Conformers for (1S,5R,6R,7S,9S,10S)-1 
were searched using the molecular mechanics force field, and four major conformers 
occupied 99% of the Boltzmann population (Table 11). The absolute 
configuration of compound 1 was established based on the good agreement between 
the calculated ECD spectrum of (1S,5R,6R,7S,9S,10S)-1 and the experimental ECD 
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Table 11. Calculated DFT B3LYP/def-SV(P) free energies, population and theoretical averaged rotary strength values for the major conformers 








DFT B3LYP/def-SV(P) Gibbs free energies in kcal/mol relative to the absolute G value for the global minimum -1880.2327 kcal/mol. 
b
In percent 
from ΔG values at 298 K and 1 atm. pi =   (K=Boltzmann constant, T =  temperature, ε = Energy). 
c







Figure 60. Absolute configuration of the HMG moiety in compound 1. Steps applied 
were of amination (a), reduction (b), and acetylation (c). Synthesis of key 
intermediate 1b: (a) (S)-1-phenylethylamine, PyBOP, Et3N, HOBt, DMF of 9 h; (b) 
LiBH4, THF of 24 h; (c) Ac2O, pyridine of 24 h. 
 
 
Figure 61. 1H NMR spectrum (chloroform-d, 600 MHz) of 1b 
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3.2.2. Compound 2 
Compound 2 was isolated as an amorphous powder with []
25
D  13.8 (c 0.3, MeOH) 
and its molecular formula of C27H44O12 was analyzed based on the HRESIMS (m/z 
559.2794 [M - H]−, calcd for C27H43O12, 559.2760). Its 1H and 13C NMR data 
revealed that compound 2 possesses a similar structure to compound 1 (Figure 62). 
The major difference found for compound 2 was in the attachment of HMG to C-1 
(δC 75.7), which was confirmed by a HMBC correlation from H-1 (δH 5.17) to C-1'' 
(δC 172.6). The HMBC correlation from the anomeric proton (δH 4.43) to C-6 (δC 
77.9) was used to establish the glycosylation position (Figure 63). NOESY 
correlations peaks of H-1/H-5, H-14/H-6, H-14/H-7, and H-14/H-9 revealed the 
relative configuration of 2 (Figure 64). To compare the chemical shift of C-1 with 
those of other analogues, compound 2 was hydrolyzed to remove the HMG moiety 
from C-1, and yielded 2a. The chemical shift of C-1 in 2a proved to be similar to 
that of previously reported compounds that possess an α-oriented hydroxy group (Hu 
et al., 2001; Zhang et al., 2003). To determine the absolute configuration of 2, ECD 
calculations were applied in which the calculated ECD spectrum of 
(1S,5R,6R,7S,9S,10R)-2 and the experimental ECD spectrum were well matched 























































































Figure 65. Comparison of experimental and calculated ECD spectra of compound 2 
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Table 12. Calculated DFT B3LYP/def-SV(P) free energies, population and theoretical averaged rotary strength values for the major conformers 









DFT B3LYP/def-SV(P) Gibbs free energies in kcal/mol relative to the absolute G value for the global minimum -1987.2041 kcal/mol. 
b
In percent 
from ΔG values at 298 K and 1 atm. pi =   (K=Boltzmann constant, T =  temperature, ε = Energy). 
c




3.2.3. Compound 3 
Compound 3, an amorphous powder with []
25
D  1.7 (c 0.5, MeOH) gave a 
molecular formula of C27H44O11 from the HRESIMS ion peak at m/z 543.2820 [M – 
H]– (calcd for C27H43O11, 543.2811). The NMR data of compound 3 showed similar 
patterns to those of 9β-O-(E-p-hydroxycinnamoyl)-1β,6β-dihydroxy-trans-eudesm-
3-en-6-O-β-D-glucopyranoside isolated from Aster koraiensis, except for the 
presence of the HMG moiety and the absence of a hydroxycinnamoyl group (Lee et 
al., 2012) (Figure 66). The HMBC correlations from H-1 (δH 4.78) to C-1'' (δC 172.5) 
and from an anomeric proton (δH 4.43) to C-6 (δC 75.2) suggested that the HMG unit 
and the glucopyranosyl group are located at C-1 and C-6, respectively (Figure 67). 
The relative configuration of compound 3 was suggested based on the NOESY cross-
peaks (Figure 68). In the NOESY spectrum, H-1 (δH 4.78) showed a correlation with 
H-5 (δH 2.57), whereas H-14 (δH 0.99) gave correlations with H-6 (δH 4.41) and H-7 
(δH 1.90). Acid hydrolysis of 3 yielded 3a. The chemical shift at C-1 (δC 77.3) of 
compound 3a was well matched with previous studies for compounds in which C-1 
(δC 79.4) with a β-oriented hydroxy group is shifted downfield compared to C-1 (δC 
72.1) in analogues with an α-oriented hydroxy group (Hu et al., 2001; Chernenko et 
al., 1994). Thus, H-1 was deduced to be α-oriented, while H-6 and H-7 were found 
to have a β-orientation. Furthermore, the β-oriented hydroxy group at C-1 showed a 
γ-gauche shielding effect over H3-14, which, in turn, resulted in an upfield chemical 
shift of C-14. The absolute configuration of compound 3 was determined by ECD 
calculations. The experimental ECD spectrum of compound 3 was in good 
agreement with the calculated spectrum of 1R,5S,6S,7R,10R of 3 (Table 13 and 
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Figure 69. Comparison of experimental and calculated ECD spectra of compound 3 
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Table 13. Calculated DFT B3LYP/def-SV(P) free energies, population and theoretical averaged rotary strength values for the major conformers 








DFT B3LYP/def-SV(P) Gibbs free energies in kcal/mol relative to the absolute G value for the global minimum -1880.2327 kcal/mol. 
b
In percent 
from ΔG values at 298 K and 1 atm. pi =   (K=Boltzmann constant, T =  temperature, ε = Energy). 
c




3.2.4. Compound 4 
Compound 4, an amorphous powder with []
25
D  31.8 (c 0.3, MeOH), was 
determined to have a molecular formula of C29H46O13, as suggested by the HRESIMS 
peaks at m/z 601.2876 [M – H]– (calcd for C29H45O13, 601.2866). The IR absorption 
of compound 4 indicated the presence of hydroxy (3389 cm−1), carbonyl (1731 cm−1), 
and olefinic (1615 cm−1) groups. NMR pattern of 4 was similar to that of 1, and 
compound 4 was found to possess an acetyl group linked to the glucopyranoside 
moiety (Figures 70-71). The HMBC correlations from the signals of H-6a' (δH 4.41) 
and the acetyl group (δH 2.04) to the acetate carbonyl carbon (δC 172.7) suggested 
that this acetyl group is attached to C-6' of the glucose (Figure 72). The 6-O-acetyl-
β-D-glucopyranosyl unit was determined to be at C-6 of the aglycone by the HMBC 
correlation from the anomeric proton (δH 4.43) to C-6 (δC 78.0). In addition, the 
position of the HMG moiety was deduced by the HMBC correlation from H-9 (δH 
4.99) to C-1'' (δC 172.8). The relative configuration of 4 was assigned based on the 
NOESY cross-peaks from H-1 (δH 3.91) to H-5 (δH 3.03) and from H-14 (δH 0.92) to 
H-6 (δH 4.40), H-7 (δH 1.54), and H-9 (δH 4.99) (Figure 73). Experimental ECD and 
calculated spectra gave the absolute configuration of compound 4 as 



























































     
 


















          

































Figure 74. Comparison of experimental and calculated ECD spectra of compound 4
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Table 14. Calculated DFT B3LYP/def-SV(P) free energies, population and theoretical averaged rotary strength values for the major conformers 








DFT B3LYP/def-SV(P) Gibbs free energies in kcal/mol relative to the absolute G value for the global minimum -1880.2327 kcal/mol. 
b
In percent 
from ΔG values at 298 K and 1 atm. pi =   (K=Boltzmann constant, T =  temperature, ε = Energy). 
c




3.2.5. Compound 5 
Compound 5 was obtained as a colorless gum with []
25
D  2.0 (c 0.5, MeOH), 
and analyzed for the molecular formula of C26H44O12 based on the HRESIMS ion 
peak at m/z 593.2812 [M + HCOO]– (calcd for C27H45O14, 593.2815). The IR 
absorption of compound 5 indicated the presence of hydroxy (3410 cm−1) and 
olefinic (1620 cm−1) groups. The chemical structure of 5 proved to be similar to that 
of compound 2 except for the attachment of the arabinopyranosyl unit at C-1 (Figures 
75-76). This was confirmed by the HMBC correlations from H-1' (δH 4.37) to C-1 
(δC 82.1) and from H-1 (δH 4.01) to C-1' (δC 105.9) (Figure 77). The ROESY 
spectrum showed the correlations between H-1 (δH 4.01) and H-5 (δH 2.97), and 
between H-6 (δH 4.43), H-7 (δH 1.46), and H-14 (δH 0.91) (Figure 78). Acid 
hydrolysis of 5 gave 5a for which the 13C NMR data were identical with those of 1c 
(Table 15). Reversed-phase HPLC analysis (co-injection) also demonstrated that 5a 
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Table 15.13C NMR data (methanol-d4, 125 MHz) of compound 1c and 5a 
 
No Compound 1c Compound 5a 
1 71.7, CH 71.7, CH 
2 34.0, CH2 33.9, CH2 
3 121.6, C 121.6, C 
4 136.1, C 136.1, C 
5 46.7, C 46.7, C 
6 78.4, CH 78.4, CH 
7 43.7, CH 43.7, CH 
8 32.4, CH2 32.4, CH2 
9 70.4, CH 70.4, CH 
10 42.9, C 42.9, C 
11 30.2, CH 30.2, CH 
12 21.6, CH3 21.6, CH3 
13 22.1, CH3 22.1, CH3 
14 12.7, CH3 12.7, CH3 
15 22.6, CH3 22.6, CH3 
1ʹ 104.9, CH 104.9, CH 
2ʹ 75.7, CH 75.7, CH 
3ʹ 78.1, CH 78.4, CH 
4ʹ 71.5, CH 71.5, CH 
5ʹ 77.8, CH 77.8, CH 
6ʹ 62.7, CH2 62.7, CH2 
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3.2.6. Compound 6 
Compound 6 was isolated as an amorphous powder with []
25
D  1.7 (c 0.2, MeOH). 
HRESIMS analysis suggested a molecular formula of C21H36O8, based on the [M + 
HCOO]–  peak at m/z 461.2382, calcd for C22H37O10, (m/z 461.2392). All the NMR 
data suggested that compound 6 was similar with compound 1 except for the absence 
of HMG (Figures 80-82). The 13C NMR data of 6 were identical with those of 1c and 
co-injection by reversed-phase HPLC analysis confirmed that compound 6 is 
identical to 1c. Furthermore, same optical rotation value of compounds 1c (1.7) and 
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Figure 83. Reversed-phase HPLC analysis of 1c (a), 6 (b), and co-injection (c) 
No Compound 1c Compound 6 
1 
71.7, CH 71.6, CH 
2 
34.0, CH2 33.9, CH2 
3 
121.6, C 121.5, C 
4 
136.1, C 136.1, C 
5 
46.7, C 46.6, C 
6 
78.4, CH 78.4, CH 
7 
43.7, CH 43.7, CH 
8 
32.4, CH2 32.4, CH2 
9 
70.4, CH 70.3, CH 
10 
42.9, C 42.9, C 
11 
30.2, CH 30.2, CH 
12 
21.6, CH3 21.6, CH3 
13 
22.1, CH3 22.1, CH3 
14 
12.7, CH3 12.7, CH3 
15 
22.6, CH3 22.6, CH3 
1ʹ 
104.9, CH 104.9, CH 
2ʹ 
75.7, CH 75.6, CH 
3ʹ 
78.1, CH 78.1, CH 
4ʹ 
71.5, CH 71.4, CH 
5ʹ 
77.8, CH 77.8, CH 
6ʹ 
62.7, CH2 62.6, CH2 
 
Table 16.13C NMR data (methanol-d4, 125 MHz) of compound 1c and 6 
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3.2.7. Compound 7 
Compound 7 was purified as a colorless gum with []
25
D  –1.6 (c 0.5, MeOH) and 
gave a molecular formula of C26H44O11 from the HRESIMS ion at m/z 577.2850 [M 
+ HCOO]– (calcd for C27H45O13, 577.2866). The broad IR peak at 3403 cm−1 and 
1630 cm−1 indicated hydroxy and olefinic groups, respectively. The NMR of 
compound 7 resembled compound 3 except for the presence of an apiofuranosyl 
group and the absence of a HMG moiety in 7 (Figures 84-85). The anomeric proton 
at δH 4.99 (d, J = 1.9 Hz) was shown to belong to an apiose moiety from a series of 
pentose proton signals [(δH 3.88, d, J = 1.8 Hz; δC 78.1), (δH 3.90, d, J = 9.6 Hz and 
δH 3.74, d, J = 9.6 Hz; δC 75.0) and (δH 3.58, s; δC 66.0)] that included two methylene 
groups based on the COSY spectrum. HMBC cross-peaks between H-1′ (δH 4.43) 
and C-6 (δC 75.7), and between H-6' (δH 3.93) of the glucose and C-1′′ (δC 110.7) of 
the apiose suggested the relative positions of the two sugar units (Figures 85-86). 
The NOESY spectrum exhibited cross-peaks from H-1 (δH 3.49) to H-5 (δH 2.45) 
and from H-14 (δH 0.87) to H-6 (δH 4.38) and H-7 (δH 1.86) (Figure 87). The sugars 
were confirmed as D-glucose and D-apiose using the method of Tanaka et al. The 
arabinofuranosyl moiety was removed by acid hydrolysis to afford 7a, and reversed-
phase HPLC on co-injection proved that 7a is identical with 3a (Figure 88). 




















Figure 84. 1H and 13C NMR spectra (CD3OD, 800/200 MHz) of compound 7 
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3 1'  






























































































Figure 88. Reversed-phase HPLC analysis of 3a (a), 7a (b), and co-injection (c) 
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3.2.8. Compound 8 
Compound 8 was isolated as an amorphous powder with []
25
D  -10.5 (c 0.1, 
MeOH). HRESIMS analysis suggested a molecular formula of C21H36O7, based on 
the [M –H]–  peak at m/z 399.2390, calcd for C21H35O7, (m/z 399.2382). The 1H NMR 
spectrum exhibited the presence of an exo-methylene protons [δH 4.95 and 1.74 (each 
1H, s)], one pair of methyl group of isopropyl [δH 0.95 (3H, d, J = 7.0 Hz) and 0.85 
(3H, d, J = 7.0 Hz) and one singlet methyl group [δH 0.74 (3H, s)] (Figure 89). The 
anomeric proton was shown at δH 4.29 (1H, d, 7.7) suggesting the presence of β-
glucopyranose. Oxygenated methylene of glucopyranose moiety was presented at δH 
3.87 (1H, dd, J = 11.7, 1.8 Hz) and 3.67 (1H, dd, J = 11.6, 5.4 Hz). With above 
spectroscopic data, compound 8 was characterized as 1β,6α-dihydroxyeudesman-









Figure 89. 1H NMR spectrum (CD3OD, 400 MHz) of compound 8 
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3.2.9. Compound 9 
Compound 9, an amorphous powder with []
25
D  -40.2 (c 0.2, MeOH), was 
determined to have a molecular formula of C19H28O6, as suggested by the HRESIMS 
peaks at m/z 351.1801 [M – H]– (calcd for C19H27O6, 351.1807). The 1H NMR data 
revealed the presence of three oxygenated protons [δH 5.21 (1H, ddd, J = 8.0, 8.0, 
4.8 Hz), 4.64 (1H, ddd, J = 11.7, 6.4, 4.3 Hz), and 4.60 (1H, d, J = 7.5 Hz)], two 
acetoxy groups [δH 2.06 (3H, s), 2.04 (3H, s)], two doublet methyl groups [δH 1.09 
(3H, d, J = 7.5 Hz), 1.03 (3H, d, J = 7.5 Hz)] and one singlet methyl group [δH 1.09 
(3H, s)]. Based on above spectroscopic data, compound 9 was confirmed as 3-










Figure 90. 1H NMR spectrum (chloroform-d, 600 MHz) of compound 9 
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3.2.10. Compound 10 
Compound 10 was purified as a colorless gum with []
25
D  34.8 (c 0.2, MeOH) and 
gave a molecular formula of C19H26O6 from the HRESIMS ion at m/z 349.1658 [M 
– H]– (calcd for C19H25O6, 349.1651). The 1H NMR spectrum showed the similar 
signals with compound 9. Three oxygenated protons [δH 5.25 (1H, ddd, J = 7.9, 7.9, 
4.8 Hz), 4.77 (1H, d, J = 7.5 Hz), and 4.68 (1H, ddd, J = 12.0, 7.8, 3.3 Hz)], one 
doublet methyl group [δH 1.06 (3H, d, J = 6.0 Hz)] and one singlet methyl group [δH 
1.08 (3H, s)] were shown (Figure 91). Two acetoxy protons were shown at [δH 2.02, 
2.08 (each 3H, s)]. The major difference was the presence of terminal methylene 
moiety [δH 6.20 (1H, d, J = 2.5 Hz) and 5.50 (1H, d, J = 2.5 Hz)] suggesting that the 
replacement of the methyl group at C-11 by exo-methylene. With above observed 
spectroscopic data, compound 10 was confirmed as 3α,4β-diacetylhymenoratin. 
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3.2.11. Compound 11 
Compound 11 was isolated as an amorphous powder with []
25
D  55.8 (c 0.1, 
MeOH). HRESIMS analysis suggested a molecular formula of C15H20O4, based on 
the [M –H]–  peak at m/z 263.1288, calcd for C15H19O4, (m/z 263.1283). The 1H NMR 
data revealed the presence of terminal methylene group [δH 6.41 (1H, s) and 5.65 
(1H, s)], one oxygenated proton [δH 4.37 (1H, m)], one doublet methyl [δH 1.22 (3H, 
d, J = 7.0 Hz)] and one singlet methyl [δH 1.01 (3H, s)]. In comparison with the 
spectroscopic data with literature, the structure of compound 11 was identified as 





















3.2.12. Compound 12 
Compound 12 was purified as a colorless gum with []
25
D  -30.4 (c 0.1, MeOH) 
and gave a molecular formula of C15H20O4 from the HRESIMS ion at m/z 263.1278 
[M – H]– (calcd for C15H19O4, 263.1283). The 1H NMR spectrum showed the 
terminal methylene group at 6.13 (1H, dd, J = 3.6, 0.9 Hz) and 6.01 (1H, dd, J = 3.3, 
0.9 Hz), one olefinic proton at δH 5.52 (1H, d, J = 1.6 Hz), one allylic methyl at δH 
1.88 (3H, d, J = 1.8 Hz) and one singlet methyl group [δH 1.23 (3H, s)]. The 13C 
NMR spectrum presented 15 carbons including carbonyl group of lactone ring at δC 
170.1, terminal methylene group at δC 121.3, double bond in pentacyclic ring at δC 
143.8 and 125.2 and allylic methyl at δC 17.9 (Figure 93). Taken together, compound 


























Figure 93. 1H and 13C NMR spectra (CD3OD, 400/100 MHz) of compound 12 
13a  13b  
3 6



















3.2.13. Compound 13 
Compound 13 was obtained as a colorless gum with []
25
D  80.5 (c 0.2, MeOH), 
and analyzed for the molecular formula of C34H37N3O6 based on the HRESIMS ion 
peak at m/z 582.2610 [M – H]– (calcd for C34H36N3O6, 582.2604). The 1H NMR 
spectrum suggested the existence of trans double bond [δH 6.85/6.81 (1H, d, J = 15.0 
Hz), 6.42 (1H, d, J = 15.0 Hz) and 6.40/6.37 (1H, d, J = 15.0 Hz)] (Figure 94). Since 
compound 13 exists as two conformational isomers, the splitting phenomenon was 
presented. The 13C NMR spectrum showed carbonyl groups at δC 169.3 and 
169.2/169.4. Methylene carbons at C-3,7,8 [δC 30.6/28.9, 27.9/26.3, 27.9/27.8] 
showed relatively upfielded chemical shift than those of methylene carbons at C-
2,4,6,9 [δC 38.2/37.9, 45.7/47.0, 49.0/47.6, 40.1/39.9] next to nitrogen. Thus, 






















































3.2.14. Compound 14 
Compound 14 was isolated as an amorphous powder with []
25
D  67.9 (c 0.2, 
MeOH). HRESIMS analysis suggested a molecular formula of C34H37N3O7, based 
on the [M –H]–  peak at m/z 598.2545, calcd for C34H36N3O7, (m/z 598.2553). Based 
on chemical formula, one hydroxyl group was deduced to be attached to compound 
13. The 1H NMR spectrum of compound 14 showed similar pattern with that of 
compound 13 except the cinnamoyl moiety connected to center N atom (Figure 95). 
The proton signal of 7'' was shifted upfield suggesting the presence of caffeoyl group 
to the center N atom. With above mentioned spectroscopic data and comparison to 
literature, compound 14 was determined as N1,N5-di-p-coumaroyl-N10-caffeoyl 























































Figure 96. Structures of isolated compounds from A. artemisiifolia. 
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3.3. Neuroprotective effects of isolated compounds from A. artemisiifolia 
AD is a fatal degenerative brain disorder that affects the elderly, and 
approximately 60-80% of AD patients progress to dementia (Femminella et al., 
2018). Many studies have demonstrated that the amyloid beta peptide is the major 
protein composition of neuritic plaques (Hong et al., 2016). Thus, many attempts 
have been made to find new chemical entities to protect the brain from Aβ-induced 
cytotoxicity. In the present study, bioassay-guided fractionation with a 70% EtOH 
extract of A. artemisiifolia led to the isolation of a total of 14 compounds from the 
EtOAc-soluble partition, which showed neuroprotective activity. To investigate the 
protective effect against the cytotoxicity induced by Aβ, HT22 cells were used, and 
were transfected with Aβ42 plasmids using Lipofectamine 2000 reagent. After 10 h 
of transfection, 40 μM of compounds 1-9, 11, 13-14, and 5 μM of compounds 10 and 
12 were added since compounds 10 and 12 showed significant cytotoxicity at 40 μM 










Figure 97. Cytotoxic effects of compounds 1-14 (40 μM) on HT22 cells 
 
Figure 98. Neuroprotective effects of isolated compounds from A. artemisiifolia 
against cytotoxicity induced by Aβ42 plasmid transfection into HT22 cells. After 10 
h of transfection, the transfected cells were exposed to the test compounds at a 







Figure 99. Compounds 5 and 6 at various concentrations. The cultures were 









Cell viability was measured by a MTT assay. Compounds 1, 2, 4-6, 8-9, 11, 
and 13-14 showed protective effects against Aβ-induced cytotoxicity (Figure 98), 
and the activity of compound 5 was comparable to that of andrographolide as a 
positive control (Figure 99). In addition, compounds 5 and 6 presented dose-
dependent activity (10, 20, and 40 μM) in Aβ42-transfected cells. Thus, flow 
cytometry analysis was performed with the selected isolates, 5 and 6. As shown in 
Figure 100, compounds 5 and 6 showed moderate decreases in fluorescence intensity 
in Aβ42-transfected HT22 cells at a concentration of 40 μM, when compared to a 
vehicle. Structure-activity relationship (SAR) analysis revealed that the 
neuroprotective effects can be attributed to the 5,10-bis-epi-eudesm-3-ene-6-O-β-D-
glucopyranosyl moiety in Aβ42-transfected cells. Among all isolates, compounds 
possessing the 5,10-bis-epi-eudesm-3-ene-6-O-β-D-glucopyranosyl moiety 

















Figure 101. HT22 cells were transfected with pEGFP-C1/Aβ42 plasmid using 
Lipofectamine 2000 reagent for 10 h. The transfected cells were then incubated with 
test compounds for 24 h, and fluorescence images were captured using a 
fluorescence microscope. Fluorescence intensity of the transfected cells was 
successfully analyzed using flow cytometry. After the Aβ42-transfected cells were 





Figure 102. Effects of compounds 1-14 on the fluorescent signal induced by pEGFP-
C1/Aβ42 plasmid transfection into HT22 cells. After 24 h of incubation with test 














Figure 103. Neuroprotective effects of Andrographolide and compound 5 against 
cytotoxicity in the Aβ42-transfected cell model. The transfected-cells were treated 
with Andrographolide (2.5 and 5 µM) and compound 5 (10, 20, and 40 µM). The 
cultures were then incubated for 24 hours and the cell proliferation was evaluated 
using the MTT method. Result was calculated as means ± SD (n = 3); *p < 0.05, **p 



































Bio-guided isolation allowed to isolate neuroprotective novel compounds. In 
the course of screening neuroprotective plants in KBNMB (Korea Bioactive Natural 
Material Bank), 70% ethanol extracted A. artemisiifolia showed strong activity. The 
total extract was analyzed by mass defect filtering method to find novel eudesmane 
sesquiterpene containing HMG group or sugar moiety. Limited mass range and well 
defined mass defect parameter enabled to filter the chromatogram. Herein, seven 
new eudesmane glycoside were isolated along with 7 known compounds. 
Compounds 1-4 were eudesmane glycosides with HMG moiety and compounds 5 
and 7 were eudesmane glycosides containing two sugar moieties. Compounds 1, 2, 
4-6, 8-9, 11, and 13-14 showed protective effects against Aβ-induced cytotoxicity in 
Aβ42-transfected HT22 cells. Compounds 5 and 6 showed most strong activity 
among the isolates. These results suggest that 70% ethanol extract A. artemissifolia 
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가시박 (Sicyos angulatus L.)는 박과 (Cucurbitaceae) 식물로써 북미가 원산인 
1 년생 덩굴식물이다. 가시박은 burcumber, one-seeded burcucumer, star-
burcucumer 등의 영문명 또는 ‘안동오이’라는 한글명으로 불리운다. 가시박은 
6~9월에 개화하며 3개에서 10개의 열매가 뭉쳐서 나는데 가시가 위협적이고 
날카롭다. 주로 강변에 많이 분포하나 장소를 가리지 않고 번식하여 주위 
생태계를 교란시켜 환경부 지정 “생태계교란 야생식물”로 분류되지만 잎과 
열매는 식품으로 지정되어 그 효과나 성분이 확인될 경우 건강기능식품으로서의 
발전가능성이 있는 식물이다. 본 식물에서는 flavonoids glycoside, steroid 등이 
분리 보고된 2편의 논문이 있으며, 최근 본 연구팀에 의하여 가시박 70% 에탄올 
추출물의 간경화 효과가 규명되었다.  가시박에 관하여 많은 연구가 보고되었지만 
대부분이 생육, 생태에 관한 연구들이며 화학성분이나 생리활성에 관한 연구는 
많지 않은 실정이다.  
본 연구팀은 식물 추출 라이브러리 은행에서 선정된 식물 추출물 300 개를 
대상으로 간지방 억제 활성 스크리닝 시험을 진행하였으며 그 결과 가시박 
추출물이 유의미한 효과를 나타내었으며 이에 단일 화합물을 분리 및 
동정하였으며 활성 평가를 시험하였다. 
비알콜성 지방간질환 (nonalcoholic fatty liver disease; NAFLD)는 지방간, 
비알콜성 지방간염, 섬유화증 및 간경변을 포함한다. 간세포 내에 중성지질 
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함량이 전체 간 무게의 5% 이상을 초과하는 상태를 말하며 인슐린 저항성 및 간 
내 염증 반응을 유도하여 지방간염을 유도하기도 한다. 비알콜성 지방간이나 
지방간염이 있는 환자의 20-40%가 결과적으로 섬유증이나 간경변을 가지게 
된다고 보고된다. 또한 비만 인구가 증가함에 따라 점차 유병률이 증가하고 
있으며 간기능 장애의 가장 흔한 원인이다. 비알콜성 지방간은 대사증후군과도 
관련되는데 이는 탄수화물의 대사에 있어서 간이 중요한 역할을 하기 때문이다. 
간은 글리코겐합성과 글리코겐분해를 통하여 혈당을 안정적으로 유지시키는데 
간의 대사에 이상이 생길 시 혈당 조절이 실패하게 되며 이는 대사증후군을 
일으키는 요인이 된다. 간경변을 가진 환자의 약 96%가 당내성을 가지며 30%의 
환자는 당뇨를 가진다고 보고된다.  
가시박 70% 에탄올 추출물은 그 구성성분이 분자네트워크 (molecular 
network)을 통하여 비슷한 화학적 구조별로 클러스터를 생성하였으며 GNPS 
라이브러리를 통하여 화학적 구조가 제시되었다. 분자네트워크 (molecular 
network) 방법은 수 많은 분자간 조각이온 패턴의 유사도를 확인함으로써 그 
유사성의 정도에 따라 서로 다른 그룹으로 구분 한다. 추출물 혹은 분획물의 
샘플은 고해상도 질량분석기를 통하여 극성별로 피크가 나뉘어 지며 이때 각각의 
피크는 조각이온 정보를 가지게 된다. 그 후 MZmine등의 프로그램을 통하여 이 
정보들이 보정되며 재가공된 정보는 GNPS 라이브러리 (https://gnps.ucsd.edu/) 
를 통하여 유사한 화학적 구조별로 cluster 를 형성하며 각각의 화학구조 또한 
제시 된다. 그 결과 가시박의 flavonoid 배당체 그룹은 크게 두개의 소그룹으로 
구분 되었으며, 그 중 하나의 소그룹은 flavonoid를 비배당체로 하여 당이 연결된 
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구조를 가지며 다른 하나의 소그룹은 flavonoid 를 비배당체로 하여 당과 
cinnamoyl 모획을 포함하는 구조인 것이 확인되었다.           
가시박 추출물은 총 추출물 및 n-hexane, Ethyl acetate, n-BuOH 등으로 
나뉘었으며 활성이 가장 좋은 Ethyl acetate 분획을 순상 및 역상 
컬럼크로마토그래피, HPLC 등을 을 이용하여 단일화홥물을 분리하였다. 총 
13종의 화합물을 분리하였으며 이 중 kaempferol 3-O-(6-O-E-feruloyl)-β-D-
glucopyranosyl-7-O-α-L-rhamnopyranoside (1), kaempferol 3-O-β-D-
apiofuranosyl-7-O-β-D-glucopyranosyl-(1→3)-α-L-rhamnopyranoside (8), 
quercetin 3-O-(6-O-E-feruloyl)-β-D-glucopyranosyl-7-O-α-L-
rhamnopyranoside (9), kaempferol 3-O-(6-O-E-feruloyl)-β-D-
glucopyranosyl-7-O-α-L-rhamnopyranosyl-(1→6)-β-D-glucopyranosyl-
(1→3)-α-L-rhamnopyranoside (11), kaempferol 3-O-(6-O-E-feruloyl)-β-D-
glucopyranosyl-7-O-β-D-glucopyranosyl-(1→3)-α-L-rhamnopyranoside 
(12), tricin 4’-O-(7’’R,8’’R-guaiacylglyceryl)ether-7-O-α-L-
rhamnopyranosyl-(1→4)-O-β-D-glucopyranoside (13)의 6종의 신규화합물을 
분리할 수 있었다. 화합물 13의 경우 flavonolignan glycoside로써 ECD 계산을 
통하여 입체구조가 결정되었다. 
분리된 13 종의 화합물을 대상으로 간세포에서의 지방축적감소 효과를 
확인하고자 하였다.   글루코스, 유리지방산, 인슐린을 처치하여 인슐린 저항성이 
유도된 HepG2 세포에 13종의 화합물 각각을 처치하였으며 감소된 중성지방의 
양은 형광키트 (Cell Biolabs, Inc, CA, USA)를 통하여 확인되었다. 중정지방 억제 
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활성을 평가한 결과 화합물 (1-4, 6, 11-13)에서 모두 억제활성이 확인되었고 그 
중 화합물 4번이 가장 뛰어난 활성을 보였다. 또한 화합물 1, 3, 4 과 13번은 10, 
20, 40 µM에서 농도의존적으로 지방의 양을 감소 시킴이 확인되었다. 화합물 
3번과 4번은 정량 시험 결과 각각 추출물 대비 15.35 ± 0.01 mg/g, 1.35 ± 0.01 
mg/g의 양을 가지는 것으로 확인되었다. 
구조적 특징에 따른 활성을 살펴보면, 분리된 화합물 중 cinnamoyl 작용기를 
가지는 kaempferol 3-O-β-D-glucoside 유도체의 경우 모두 간 중성지방의 
억제효과를 보였고 이는 기존 연구 결과들과 일치하였다. 또한 화합물 13번의 
경우 간보호 효과로 널리 알려진 실리마린의 성분들과 유사한 구조를 가지고 있다.  
본 연구는 가시박 70% 에탄올 추출물과 이로부터 분리된 단일 화합물이 지방간 
감소에 효과가 있다는 것을 제시하였다. 
 
Part 2    
   돼지풀 (Ambrosia artemisiifolia L)은 국화과 (Asteraceae) 식물로써 북미가 
원산인 1 년생 초본 식물이다. 돼지풀이란 이름은 영국의 hogweed 에서 
유래하였으며 들이나 밭에 자라는 특징을 가진다. 또한 돼지풀은 가시박과 함께 
대표적인 생태계 교란식물로써 높은 번식력과 타 식물과의 경쟁에서 우위를 
점하는 특성으로 인해 전국에 걸쳐 분포하는 잡초이다. 전체에 굳센 털이 많으며 
가지가 많이 갈라지고 줄기는 1.5m 까지 곧추서며 8-9 월에 개화한다. 
‘단풍잎돼지풀’과 달리 잎이 손바닥 모양이 아닌 깃꼴로 갈라진다. 돼지풀에서는 
215 
 
sesquiterpene, triterpene 과 caffeic acid 유사체가 분리, 동정되었으며 
항산화효과 항균효과등이 보고되어 있다. 
본 연구팀은 식물 추출 라이브러리 은행에서 선정된 식물 추출물 300 개를 
대상으로 뇌 신경보호 활성 스크리닝 시험을 진행하였으며 그 결과 돼지풀 
추출물이 유의미한 활성 효과를 나타내어 추가적으로 추출물 중 활성분획에 관한 
화합물 분리, 동정을 진행하였다. 
알츠하이머 질환에서는 대뇌피질 속 신경세포의 손실로 인하여 뇌회의 위축이 
발생하며 신경반과 신경원섬유농축을 보이는 특징을 가진다. 신경반은 
독성물질인 베타아밀로이드(Aβ)가 응결되어 뇌신경세포를 둘러싸며 그 주변을 
염증 세포가 둘러싸고 있는 형태를 나타낸다. 이는 강한 신경 독성을 유발하여 
세포 사멸을 일으키고 신경퇴행을 유도하여 알츠하이머질환을 유발한다. 현재 
전세계적으로 약 3 천만명의 인구가 알츠하이머 병으로 고통받고 있으며 
세계보건기구 (WHO)는 향후 20 년간 이 숫자가 3 배 증가할 것이라 예측하고 
있다.  
질량결손필터링 (mass defect filtering)은 2 차 대사산물의 종류별로 
기본골격을 이루는 수소, 산소, 질소 등의 원자의 비율이 다름을 이용하여 
표적하는 특정 종류의 생리활성 물질을 분류하는데 정보를 제공한다. 탄소의 경우 
12.0000의 원자량을 가지며 수소, 산소의 경우에는 각각 1.0078, 15.9949의 값을 
가지게 되므로 수소 대비 산소의 비율이 높아질수록 낮은 질량결손 값을 가지며 
이와 같은 원리를 이용해 표적 물질을 분류할 수 있다. 본 연구를 진행하는 중 
eudesmane 배당체가 뇌신경 보호에 활성을 나타내는 것이 확인되었으며 또한 
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HMG (3′′-hydroxy-3′′-methylglutaryl) 기가 존재하는 eudesmane 배당체 혹은 
2 개 이상의 당분자를 포함한 eudesmane 의 경우 신규화합물로 판별되었기에 
질량결손필터링을 통하여 eudesmane 배당체 혹은 HMG 기를 포함하는 
eudesmane 배당체를 분리 및 동정하였다. 또한 질량결손필터링을 하는 과정에서 
이를 보완하는 방법으로 분획물단계에서의 NMR 스크리닝을 실시하였다. 
Silicagel를 통하여 극성별로 5개의 분획을 얻은 다음 Sephadex-LH20 컬럼을 
이용하여 5개분획 각각에 대하여 페놀성화합물과 terpene을 구분 하였다. 각각의 
terpene 분획을 1H-NMR 로 스크리닝하여 HMG 에서 특징적으로 나타나는 
메틸렌 프로톤의 존재를 확인하였다.  
돼지풀 추출물은 총 추출물 및, n-hexane, Ethyl acetate, n-BuOH 등으로 
나뉘었으며 활성이 가장 뛰어난 Ethyl acetate 분획을 순상 및 역상 
컬럼크로마토그래피, Sephadex-LH20, HPLC 등을 이용하여 단일화합물을 
분리하였다. 총 14종의 (1-14) 화합물이 분리되었으며 eudesmane 배당체 (1-8), 














D-glucopyranoside (7)의 7종의 신규화합물을 분리하였다. 화합물 1-4의 경우 
ECD 계산을 통하여 비당체의 절대구조를 정하였으며 화합물 1의 HMG의 경우 
기존의 연구결과를 참고하여 amination, reduction, acetylation등의 과정을 거쳐 
절대구조를 결정하였다. 가수분해 과정을 통하여 화합물 1 에서 HMG 를 
제거하였으며 이 화합물은 13C-NMR, HPLC 등을 통하여 화합물 6과 동일함을 
확인하여 화합물 6 의 절대 구조를 규명하였다. 화합물 5 번과 7 번의 경우도 
동일하게 가수분해를 통하여 특정 당이 제거되었으며 이는 각각 HMG 기가 
제거된 1 번과 3 번과 동일한 반응생성물임을 확인함으로써 절대구조를 
결정하였다.  
분리된 14 종의 화합물을 대상으로 뇌신경보호 효과를 확인하고자 하였다. 
pEGFP-C1/Aβ 42 플라스미드를 Lipofectamine 2000 regent 와 함께 HT-22 
cell로 도입하여 10 시간 반응시킨 후 14종의 화합물을 각각 처치하여 화합물의 
세포보호 효과를 관찰하였다. 화합물 1, 2, 4-6, 8-9, 11 그리고 13-14 번 
화합물에서 뇌신경 보호효과가 나타났으며 화합물 5번과 6번은 10, 20, 40µM 
에서 농도의존적으로 효과를 보였다. 
본 연구는 돼지풀 70% 에탄올 추출물과 이로부터 분리된 단일 화합물이 
뇌신경보호에 효과가 있다는 것을 제시하였다. 
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